1
|
Bataille P, Lebrun-Vignes B, Bettuzzi T, Ingen-Housz-Oro S, Hadj-Rabia S, Welfringer-Morin A, Bodemer C. Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis. J Eur Acad Dermatol Venereol 2024. [PMID: 38682703 DOI: 10.1111/jdv.20054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 04/11/2024] [Indexed: 05/01/2024]
Abstract
BACKGROUND Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare life-threatening mucocutaneous reactions most often induced by drugs. To date, no large pharmacovigilance study has been conducted in the paediatric population. OBJECTIVES To describe the spectrum of drugs associated with SJS-TEN in children through the analysis of cases reported in the WHO pharmacovigilance database (VigiBase). METHODS Disproportionality study using data from VigiBase. All paediatric (age under 18 years) cases reported between January 1, 1967, and July 6, 2022, were included. For each molecule, a case-non-case study was performed to assess a potential pharmacovigilance signal by computing the lower end of the 95% credibility interval for the information component (IC025). We performed sensitivity analyses, (i) taking into account only cases reported by physicians and (ii) taking into account only cases reported in the last 10 years. RESULTS Among 31,376,783 adverse drug reactions reported in VigiBase, 2,248,727 were paediatric cases and 7342 were encoded as paediatric SJS-TEN. Significant statistical pharmacovigilance signals were observed for 165 drugs. The two most represented drug classes were antiepileptics and anti-infectious drugs. The five drugs with the highest IC025 were lamotrigine (IC025 4.99), carbamazepine (IC025 4.88), phenobarbital (IC025 4.67), phenytoin (IC025 4.52) and nimesulide (IC025 4.23). Acetaminophen was significantly associated with paediatric SJS-TEN (IC025 2.85) and we also described various new suspected drugs. Vaccines had no significant pharmacovigilance signal. These results were confirmed with the sensitivity analyses. CONCLUSIONS This study updates the spectrum of drugs potentially associated with paediatric SJS-TEN.
Collapse
Affiliation(s)
- Pauline Bataille
- Department of Pediatric Dermatology, Hôpital Necker-Enfants Malades Hospital, APHP, Paris City University, Paris, France
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
- General Paediatrics, Department of Infectious Disease and Internal Medicine, Robert Debré Mother-Child University Hospital, AP-HP, Paris, France
- Paris City University, Imagine Institute, Data Science Platform, INSERM UMR 1163, Paris, France
| | - Benedicte Lebrun-Vignes
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
- Regional Pharmacovigilance Center, Department of Pharmacology, AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France
- Université Paris Est Créteil EpidermE, UPEC, Créteil, France
| | - Thomas Bettuzzi
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
- Regional Pharmacovigilance Center, Department of Pharmacology, AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France
- Université Paris Est Créteil EpidermE, UPEC, Créteil, France
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
- Université Paris Est Créteil EpidermE, UPEC, Créteil, France
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Smail Hadj-Rabia
- Department of Pediatric Dermatology, Hôpital Necker-Enfants Malades Hospital, APHP, Paris City University, Paris, France
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Anne Welfringer-Morin
- Department of Pediatric Dermatology, Hôpital Necker-Enfants Malades Hospital, APHP, Paris City University, Paris, France
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Christine Bodemer
- Department of Pediatric Dermatology, Hôpital Necker-Enfants Malades Hospital, APHP, Paris City University, Paris, France
- Reference Center of Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
2
|
Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, Quereux G, Faiz S, de Vicq de Cumptich M, Ram-Wolff C, Janela-Lapert R, Guenova E, Lheure C, Le Corre Y, Adamski H, Blanchard M, Bonnet N, Amatore F, Grange F, Troin L, Bagot M, Beylot-Barry M. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study). Br J Dermatol 2024:ljae153. [PMID: 38660811 DOI: 10.1093/bjd/ljae153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 03/30/2024] [Accepted: 04/24/2024] [Indexed: 04/26/2024]
Abstract
The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients.
Collapse
Affiliation(s)
- Sofia Tzoumpa
- Department of Dermatology, Henri-Mondor University Hospital, AP-HP , Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri-Mondor University Hospital, AP-HP , Créteil, France
- Paris Est Créteil University, EpiDermE, Créteil, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Anne Pham-Ledard
- Department of Dermatology, INSERM 1312, Bordeaux University Hospital, Bordeaux, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | | | - Olivier Dereure
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Gaëlle Quereux
- Department of Dermatology, CHU Nantes, Nantes University, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Sarah Faiz
- Department of Dermatology, Lille University Hospital, Lille, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Marine de Vicq de Cumptich
- Department of Dermatology, Saint-Pierre, Brugmann University Hospitals, Brussels, Belgium and Department of Hematology Bordet Institute, Brussels, Belgium
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Raphaël Janela-Lapert
- Department of Dermatology, Rouen University Hospital, Rouen, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Emmanuella Guenova
- Department of Dermatology, Lausanne University Hospital, and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Coralie Lheure
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Yannick Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Henri Adamski
- Department of Dermatology, Rennes University Hospital, Rennes, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Maël Blanchard
- Department of Dermatology, Lausanne University Hospital, and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Nathalie Bonnet
- Department of Dermatology, Hôpital Nord, AP-HM, Marseille, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Florent Amatore
- Department of Dermatology, Hôpital Nord, AP-HM, Marseille, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Florent Grange
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Laura Troin
- Department of Dermatology, Nice University Hospital, Nice, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, Paris, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| | - Marie Beylot-Barry
- Department of Dermatology, INSERM 1312, Bordeaux University Hospital, Bordeaux, France
- French Cutaneous Lymphomas Study Group (GFELC), France
| |
Collapse
|
3
|
Brüggen MC, Traidl S, Mitamura Y, Walsh S, French LE, Gulati N, Phillips E, Maverakis E, Ingen-Housz-Oro S. Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients. Allergy 2024. [PMID: 38587051 DOI: 10.1111/all.16122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 03/15/2024] [Accepted: 03/31/2024] [Indexed: 04/09/2024]
Affiliation(s)
- Marie-Charlotte Brüggen
- Faculty of Medicine, University Zurich, Zurich, Switzerland
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
- ToxiTEN group of the ERN-skin
| | - Stephan Traidl
- Faculty of Medicine, University Zurich, Zurich, Switzerland
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
| | - Yasutaka Mitamura
- Swiss Institute of Allergy and Asthma Research (SIAF) Davos, Davos, Switzerland
| | - Sarah Walsh
- ToxiTEN group of the ERN-skin
- Department of Dermatology, King's College Hospital NHS Foundation Trust, London, UK
| | - Lars E French
- ToxiTEN group of the ERN-skin
- Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany
- Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA
| | - Nicholas Gulati
- The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Elizabeth Phillips
- Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Emanual Maverakis
- Department of Dermatology, University of California, Davis, California, USA
| | - Saskia Ingen-Housz-Oro
- ToxiTEN group of the ERN-skin
- Department of Dermatology, Henri Mondor Hospital, Univ Paris Est Créteil EpidermE, Créteil, Paris, France
- Reference center for severe drug reactions TOXIBUL, Créteil, France
| |
Collapse
|
4
|
Beaulieu V, Matei I, Bel Hareth K, Ingen-Housz-Oro S, Assier H. Unveiling the hidden culprit: A case report of recurrent SDRIFE caused by a systemic corticosteroid masquerading as antibiotic allergies. Contact Dermatitis 2024. [PMID: 38572964 DOI: 10.1111/cod.14558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 03/19/2024] [Accepted: 03/26/2024] [Indexed: 04/05/2024]
Affiliation(s)
- Valérie Beaulieu
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Ilaria Matei
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Kamar Bel Hareth
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Haudrey Assier
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
5
|
Matthys A, Bardel B, Le Bras F, Créange A, Nordine T, Gounot R, Ingen-Housz-Oro S, Carvalho M, Lefaucheur JP, Haioun C, Planté-Bordeneuve V, Gendre T. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy. Eur J Neurol 2024:e16285. [PMID: 38511878 DOI: 10.1111/ene.16285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 03/05/2024] [Accepted: 03/06/2024] [Indexed: 03/22/2024]
Abstract
BACKGROUND AND PURPOSE Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV-induced neuropathy (BV-CN) is a mild distal sensory axonal polyneuropathy. Severe BV-induced inflammatory neuropathies (BV-IN) have been described. BV-IN contribute to lymphoma-associated morbidity but might be immunotherapy-responsive. Our primary objective was to evaluate the rate of BV-IN. Our secondary objectives were to determine risk factors and warning signs. METHODS We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV-induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV-IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV-CN. RESULTS Among 83 patients, 41 (49%) developed neuropathy: 35 BV-CN and 6 BV-IN. Thus, the rate of BV-IN was 7.2%. Compared to patients with BV-CN, no predisposing factor was identified. However, patients with BV-IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV-IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy. CONCLUSIONS Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Collapse
Affiliation(s)
- Arthur Matthys
- Department of Neurology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Center for Interdisciplinary Research in Biology, Collège de France, CNRS UMR 7241, INSERM U1050, Labex Memolife, PSL Research University, Paris, France
| | - Benjamin Bardel
- Unit of Clinical Neurophysiology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France
| | - Fabien Le Bras
- Lymphoid Malignancies Unit, AP-HP, Henri Mondor University Hospital, Créteil, France
| | - Alain Créange
- Department of Neurology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France
| | - Tarik Nordine
- Unit of Clinical Neurophysiology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France
| | - Romain Gounot
- Lymphoid Malignancies Unit, AP-HP, Henri Mondor University Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Paris-Est Créteil University EpiDermE, AP-HP, Henri Mondor University Hospital, Créteil, France
| | - Muriel Carvalho
- Department of Pharmacy, AP-HP, Henri Mondor University Hospital, Créteil, France
| | - Jean-Pascal Lefaucheur
- Unit of Clinical Neurophysiology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France
| | - Corinne Haioun
- Lymphoid Malignancies Unit, AP-HP, Henri Mondor University Hospital, Créteil, France
| | - Violaine Planté-Bordeneuve
- Department of Neurology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France
| | - Thierry Gendre
- Department of Neurology, AP-HP, Henri Mondor University Hospital, Créteil, France
- Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France
| |
Collapse
|
6
|
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, Prost-Squarcioni C, Labeille B, Picard-Dahan C, Chaby G, Richard MA, Tancrede-Bohin E, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Musette P, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D’Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial. JAMA Dermatol 2024; 160:290-296. [PMID: 38265821 PMCID: PMC10809134 DOI: 10.1001/jamadermatol.2023.5679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 11/03/2023] [Indexed: 01/25/2024]
Abstract
Importance The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. Objective To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. Design, Setting, and Participants This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015. Exposure Patients were initially randomized in the rituximab plus prednisone group or prednisone-alone group. Main outcomes and measures The primary outcome was the 5- and 7-year disease-free survival (DFS) without corticosteroids, assessed by Kaplan-Meier curves. Secondary outcomes were occurrence of relapse, occurrence of severe adverse events (SAEs), and evolution of antidesmoglein (Dsg) antibody enzyme-linked immunosorbent assay values to predict long-term relapse. Results Of the 90 patients in the Ritux 3 trial, 83 were evaluated at the end of follow-up study visit (44 in the rituximab plus prednisone group; 39 in the prednisone-alone group) with a median (IQR) follow-up of 87.3 (79.1-97.5) months. Forty-three patients (93%) from the rituximab plus prednisone and 17 patients (39%) from the prednisone-alone group had achieved complete remission without corticosteroids at any time during the follow-up. Patients from the rituximab group had much longer 5- and 7-year DFS without corticosteroids than patients from the prednisone-alone group (76.7% and 72.1% vs 35.3% and 35.3%, respectively; P < .001), and had about half the relapses (42.2% vs 83.7%; P < .001). Patients who received rituximab as second-line treatment had shorter DFS than patients treated as first line (P = .007). Fewer SAEs were reported in the rituximab plus prednisone group compared with the prednisone-alone group, 31 vs 58 respectively, corresponding to 0.67 and 1.32 SAEs per patient, respectively (P = .003). The combination of anti-Dsg1 values of 20 or more IU/mL and/or anti-Dsg3 values of 48 or more IU/mL yielded 0.83 positive predictive value and 0.94 negative predictive value to predict long-term relapse. Conclusions and Relevance In this secondary analysis of the Ritux 3 trail, first-line treatment of patients with pemphigus with the Ritux 3 regimen was associated with long-term sustained complete remission without corticosteroid therapy without any additional maintenance infusion of rituximab.
Collapse
Affiliation(s)
- Billal Tedbirt
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Maud Maho-Vaillant
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Estelle Houivet
- Department of Biostatistics and Clinical Research, CHU Rouen, Rouen, France
| | - Claire Mignard
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Marie-Laure Golinski
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Sébastien Calbo
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Catherine Prost-Squarcioni
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint-Étienne, Saint-Étienne, France
| | | | - Guillaume Chaby
- Department of Dermatology, University of Amiens, Amiens, France
| | - Marie-Aleth Richard
- CEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Dermatology Department, Universitaire Hospital Timone, Assistance Publique Hôpitaux de Marseille, APHM, 13385, Marseille, France
| | | | | | | | | | - Frédéric Caux
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Marina Alexandre
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Philippe Musette
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Univ Paris Est Créteil EpiDermE, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Gaëlle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sébastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
| | | | - Michel D’Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, APHP and University of Paris cité, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Jacques Benichou
- Department of Biostatistics and Clinical Research, CHU Rouen and Inserm U1018, Université Paris-Saclay and Université de Rouen, Rouen, France
| | - Pascal Joly
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Vivien Hébert
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
7
|
Beaulieu V, Matei I, Hajjar N, Ingen-Housz-Oro S, Assier H. Acute allergic contact dermatitis caused by sulphites in a cosmetic and a pharmaceutical cream. Contact Dermatitis 2024; 90:312-314. [PMID: 38037715 DOI: 10.1111/cod.14468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 11/14/2023] [Accepted: 11/16/2023] [Indexed: 12/02/2023]
Affiliation(s)
- Valérie Beaulieu
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Department of Dermatology, Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, Canada
| | - Ilaria Matei
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Nancy Hajjar
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Haudrey Assier
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
8
|
Annabi E, Lalevée S, Bettuzzi T, Demortier J, Papouin B, De Mestier Du Bourg L, Sbidian E, Ingen-Housz-Oro S. Annular eruption with weight loss in a 47-year-old man. Frontline Gastroenterol 2024; 15:177-178. [PMID: 38486674 PMCID: PMC10935518 DOI: 10.1136/flgastro-2023-102507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 09/04/2023] [Indexed: 03/17/2024] Open
Affiliation(s)
| | | | | | | | - Barbara Papouin
- Pathology, Hopital Henri Mondor, Creteil, Île-de-France, France
| | | | - Emilie Sbidian
- Dermatology, Hopital Henri Mondor, Creteil, France
- Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, UPEC, Creteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology, Hopital Henri Mondor, Creteil, France
- Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, UPEC, Creteil, France
| |
Collapse
|
9
|
Bettuzzi T, Hoisnard L, Beytout Q, Ingen-Housz-Oro S, Sbidian E. Validation of an Algorithm to Identify Epidermal Necrolysis on a Medico-Administrative Database. J Invest Dermatol 2024; 144:708-710.e7. [PMID: 37832841 DOI: 10.1016/j.jid.2023.09.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/15/2023]
Affiliation(s)
- Thomas Bettuzzi
- Dermatology Department, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris Est Créteil University (UPEC), Créteil, France; Toxic Bullous Dermatoses and Severe Drug Reactions Reference Center, TOXIBUL, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France.
| | - Léa Hoisnard
- Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris Est Créteil University (UPEC), Créteil, France; University Hospital Federation (FHU) TRUE (InnovaTive theRapy for immUne disordErs), Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; INSERM, Clinical Investigation Centre 1430, Henri Mondor Hospital, Créteil, France
| | - Quentin Beytout
- Dermatology Department, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris Est Créteil University (UPEC), Créteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris Est Créteil University (UPEC), Créteil, France; Toxic Bullous Dermatoses and Severe Drug Reactions Reference Center, TOXIBUL, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France
| | - Emilie Sbidian
- Dermatology Department, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris Est Créteil University (UPEC), Créteil, France; University Hospital Federation (FHU) TRUE (InnovaTive theRapy for immUne disordErs), Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; INSERM, Clinical Investigation Centre 1430, Henri Mondor Hospital, Créteil, France
| |
Collapse
|
10
|
Matei I, Weill A, Hareth KB, Ingen-Housz-Oro S, Assier H. DRESS to loxapine and avoidable recurrence with clozapine. Contact Dermatitis 2024; 90:191-192. [PMID: 37990777 DOI: 10.1111/cod.14458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 09/19/2023] [Accepted: 10/20/2023] [Indexed: 11/23/2023]
Affiliation(s)
- Ilaria Matei
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Amandine Weill
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Kamar Bel Hareth
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Créteil, France
| | | | - Haudrey Assier
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Créteil, France
| |
Collapse
|
11
|
Ingen-Housz-Oro S, Joly P, Kini-Matondo W, Sbidian E. Prevention of recurrent erythema multiforme with lenalidomide: a case series. Clin Exp Dermatol 2024; 49:166-168. [PMID: 37683088 DOI: 10.1093/ced/llad314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 09/02/2023] [Accepted: 09/21/2023] [Indexed: 09/10/2023]
Abstract
Prevention of recurrences of erythema multiforme is a therapeutic challenge. Thalidomide is effective, but its use is limited by adverse effects, especially peripheral neuropathy. We report seven cases of recurrent severe erythema multiforme treated with lenalidomide. In six cases, the drug was effective without significant adverse effects.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology Department
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL), Créteil, France
- University Paris Est Créteil Val de Marne EpiDermE, Créteil, France
| | - Pascal Joly
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL), Créteil, France
- Dermatology Department, Charles Nicolle University Hospital, Rouen, France
| | | | - Emilie Sbidian
- Dermatology Department
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL), Créteil, France
- University Paris Est Créteil Val de Marne EpiDermE, Créteil, France
| |
Collapse
|
12
|
Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, Ingen-Housz-Oro S, Pham-Ledard A, Bedane CR, Picard-Dahan C, Berthin C, Dereure O, Konstantinou MP, Castel M, Jouen F, Joly P, Seta V, Duvert-Lehembre S, Le Roux C, Quereux G, Sassolas B, Brenaut E, Sin C, Richard MA, Bérard F, Giusti D, Belmondo T, Gille T, Caux F, Prost-Squarcioni C, Grootenboer-Mignot S, Alexandre M. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol 2024; 190:258-265. [PMID: 37792727 DOI: 10.1093/bjd/ljad369] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 09/18/2023] [Accepted: 09/21/2023] [Indexed: 10/06/2023]
Abstract
BACKGROUND Interest in the use of omalizumab to treat bullous pemphigoid (BP) in the event of resistance or contraindication to conventional therapies is currently based on limited evidence. OBJECTIVES To assess the effectiveness and safety of omalizumab in BP and to identify predictive factors in response to treatment. METHODS We conducted a French national multicentre retrospective study including patients with a confirmed diagnosis of BP treated with omalizumab after failure of one or several treatment lines. We excluded patients with clinically atypical BP, as per Vaillant's criteria. The criteria for clinical response to omalizumab were defined according to the 2012 international consensus conference. Anti-BP180-NC16A IgE enzyme-linked immunosorbent assay was performed on sera collected before initiating omalizumab, when available. RESULTS Between 2014 and 2021, 100 patients treated in 18 expert departments were included. Median age at diagnosis was 77 years (range 20-98). Complete remission (CR) was achieved in 77% of patients, and partial remission in an additional 9%. CR was maintained 'off therapy' in 11.7%, 'on minimal therapy' in 57.1%, and 'on non-minimal therapy' in 31.2%. Median time to CR was 3 months (range 2.2-24.5). Relapse rate was 14%, with a median follow-up time of 12 months (range 6-73). Adverse events occurred in four patients. CR was more frequently observed in patients with an increased serum baseline level of anti-BP180-NC16A IgE (75% vs. 41%; P = 0.011). Conversely, urticarial lesions, blood total IgE concentration or eosinophil count were not predictive of CR. Patients with an omalizumab dosage > 300 mg every 4 weeks showed a similar final outcome to those with a dosage ≤ 300 mg every 4 weeks, but control of disease activity [median 10 days (range 5-30) vs. 15 days (range 10-60); P < 0.001] and CR [median 2.4 months (range 2.2-8.2) vs. 3.9 months (range 2.3-24.5); P < 0.001] were achieved significantly faster. CONCLUSIONS We report the largest series to date of BP treated by omalizumab and confirm its effectiveness and safety in this indication. Serum baseline level of anti-BP180-NC16A IgE may predict response to treatment.
Collapse
Affiliation(s)
- Réda Chebani
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Florian Lombart
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Guillaume Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Ali Dadban
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Christelle Le Roux
- Department of Dermatology and Referral Centre for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | | | | | | | | | | | | | | | | | | | - Frédéric Caux
- Department of Dermatology and Referral Centre for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | - Catherine Prost-Squarcioni
- Department of Dermatology and Referral Centre for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | | | - Marina Alexandre
- Department of Dermatology and Referral Centre for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| |
Collapse
|
13
|
Ingen-Housz-Oro S, Elshot YS, Segura S, Marchand A, Pouessel D, Kluger N, de Barros Silva G, Ortiz-Brugues A, Aubert M, Saldana C, Mavroudis D, Burle E, Tournier E, Koumaki D, Sibaud V. Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm. J Eur Acad Dermatol Venereol 2024; 38:e99-e101. [PMID: 37607297 DOI: 10.1111/jdv.19454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 08/18/2023] [Indexed: 08/24/2023]
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Univ Paris Est Créteil EpiDermE, Créteil, France
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
| | - Yannick S Elshot
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Sonia Segura
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Dermatology Department, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain
| | - Antoine Marchand
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Dermatology Unit, Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Damien Pouessel
- Oncology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France
| | - Nicolas Kluger
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Dermatology Department, Helsinki University Hospital, Helsinki, Finland
| | - Giselle de Barros Silva
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Dermatology Department, Hospital 12 de Octubre, Madrid, Spain
| | - Ariadna Ortiz-Brugues
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Oncology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France
| | - Marine Aubert
- Oncology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Carolina Saldana
- Oncology Department, AP-HP, Henri Mondor Hospital, Créteil, France
- Univ Paris Est Creteil, TRePCa, Créteil, France
| | - Dimitrios Mavroudis
- Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece
| | - Estelle Burle
- Oncology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France
| | - Emilie Tournier
- Department of Pathology, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France
| | - Dimitra Koumaki
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Department of Dermatology and Venereology, University Hospital of Heraklion, Crete, Greece
| | - Vincent Sibaud
- Dermatology for Cancer Patients EADV Task Force, Toulouse, France
- Oncology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France
| |
Collapse
|
14
|
Brüggen MC, Walsh S, Ameri MM, Anasiewicz N, Maverakis E, French LE, Ingen-Housz-Oro S. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus. JAMA Dermatol 2024; 160:37-44. [PMID: 37966824 PMCID: PMC10652220 DOI: 10.1001/jamadermatol.2023.4450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 08/28/2023] [Indexed: 11/16/2023]
Abstract
Importance Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment. Objective To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS. Design, Setting, and Participants The Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS. Fifty-seven international experts in DRESS were invited, and 54 participated in the survey, which took place from July to September 2022. Main Outcomes/Measures The degree of agreement was calculated with the RAND-UCLA Appropriateness Method. Consensus was defined as a statement with a median appropriateness value of 7 or higher (appropriate) and a disagreement index of lower than 1. Results In the first Delphi round, consensus was reached on 82 statements. Thirteen statements were revised and assessed in a second round. A consensus was reached for 93 statements overall. The experts agreed on a set of basic diagnostic workup procedures as well as severity- and organ-specific further investigations. They reached a consensus on severity assessment (mild, moderate, and severe) based on the extent of liver, kidney, and blood involvement and the damage of other organs. The panel agreed on the main lines of DRESS management according to these severity grades. General recommendations were generated on the postacute phase follow-up of patients with DRESS and the allergological workup. Conclusions and Relevance This Delphi exercise represents, to our knowledge, the first international expert consensus on diagnostic workup, severity assessment, and management of DRESS. This should support clinicians in the diagnosis and management of DRESS and constitute the basis for development of future guidelines.
Collapse
Affiliation(s)
- Marie-Charlotte Brüggen
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Zurich, Switzerland
- Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland
- ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France
| | - Sarah Walsh
- ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France
- Department of Dermatology, King’s College Hospital, London, England, United Kingdom
| | - M. Milad Ameri
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Zurich, Switzerland
- Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland
| | - Natalie Anasiewicz
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - Emanual Maverakis
- Department of Dermatology, University of California, Davis, Sacramento, California
| | - Lars E. French
- ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France
- Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
- Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida
| | - Saskia Ingen-Housz-Oro
- ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France
- Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France
- Toxic Bullous Dermatoses TOXIBUL Reference Center, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France
- Univ Paris Est Créteil EpiDermE, Créteil, France
| | | |
Collapse
|
15
|
Ou S, Tancrède-Bohin E, Alexandre M, Ingen-Housz-Oro S, Castel M, Debarbieux S, Duvert-Lehembre S, Konstantinou MP, Abasq C, Berthin C, Couzan C, Lepelletier C, Jelti L, Bouteiller J, Calugareanu A, Véron M, Caux F, Joly P, Thomas B, Viguier M. Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study. J Am Acad Dermatol 2024; 90:204-208. [PMID: 37769901 DOI: 10.1016/j.jaad.2023.08.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 08/16/2023] [Accepted: 08/20/2023] [Indexed: 10/03/2023]
Affiliation(s)
- Sokounthie Ou
- Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France
| | - Emmanuelle Tancrède-Bohin
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Marina Alexandre
- Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM UMR1125, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, University Paris Est Créteil, EpidermE, Créteil, France
| | - Marion Castel
- Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
| | - Sébastien Debarbieux
- Department of Dermatology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France
| | - Sophie Duvert-Lehembre
- Department of Dermatology, Lille University Hospital, Lille, France; Department of Dermatology, Dunkerque Hospital, Dunkerque, France
| | | | - Claire Abasq
- Department of Dermatology, Augustin-Morvan Hospital, Brest, France
| | | | - Caroline Couzan
- Department of Dermatology, Saint-Étienne Hospital, Saint-Étienne, France
| | - Clémence Lepelletier
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Lamia Jelti
- Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, University Paris Est Créteil, EpidermE, Créteil, France
| | - Julie Bouteiller
- Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
| | | | - Marie Véron
- Department of Dermatology, Lille University Hospital, Lille, France
| | - Frédéric Caux
- Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM UMR1125, Bobigny, France
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
| | - Bérenger Thomas
- Department of Epidemiology, Faculty of Medicine, Sorbonne University, Paris, France
| | - Manuelle Viguier
- Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France.
| |
Collapse
|
16
|
Marcombes C, Ingen-Housz-Oro S, Dezoteux F, Staumont-Sallé D, Milpied B, Tetart F, de Prost N, Fourati S, Ortonne N, Kasimir F, Prusty BK, Descamps V. Retrospective study on the association of human herpesvirus reactivation with severe DRESS: A description of blood and skin reactivations. J Eur Acad Dermatol Venereol 2023; 37:2550-2557. [PMID: 37591509 DOI: 10.1111/jdv.19425] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 07/17/2023] [Indexed: 08/19/2023]
Abstract
BACKGROUND Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe adverse event (mortality of 10%). Its pathophysiology involves herpesviruses, particularly HHV-6, but the exact mechanisms are still poorly understood. OBJECTIVE To describe severe cases of DRESS and especially their association with herpesvirus reactivation. METHODS This study was a multicentre case series conducted between 2007 and 2021 at five University Hospital Centres in France. The study included patients who had severe DRESS, which was defined as death, transfer to the intensive care unit (ICU), or severe damage to internal organs. We excluded patients without blood PCR sample, without a drug formally attributed or with RegiSCAR score < 6. We collected data on severity, causative drug, associated visceral damage and results of viral blood PCRs. HHV-6 reactivation was studied in skin biopsies by detection of small non-coding transcripts (HHV-6 miR-aU14) and a late viral protein (GP82/105). RESULTS Fifty-two patients were included (29 female, median age 62, interquartile range (IQR) [37;72]). Eight patients (15%) died, 13 (27%) were admitted to ICU. Most patients (n = 34; 65%) had multisystem involvement: most frequent was liver (n = 46; 88%), then renal failure (n = 24; 46%). Forty patients (77%) had at least one blood viral reactivation among HHV-6, EBV or CMV, of which 21 (53%) had at least two. Median time of blood HHV-6 reactivation was 24 days (IQR [20;35]). HHV-6 reactivation was demonstrated in 15 out of 20 skin biopsies, with a median time of 11 days [9;17]. CONCLUSIONS We confirmed the high rate of HHV-6 reactivation in severe DRESS and demonstrated cutaneous HHV-6 reactivation using small non-coding transcripts (HHV-6 miR-aU14), which preceded viral PCR positivity in blood. These results suggest that HHV-6 reactivation during DRESS may start in skin. Furthermore, search for miR-aU14 in skin biopsy could become a useful diagnostic tool for early detection of HHV-6 reactivation.
Collapse
Affiliation(s)
- C Marcombes
- Department of Dermatology, AP-HP, Bichat Hospital, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Epiderme, Paris Est Créteil University, Créteil, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
| | - F Dezoteux
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, CHU Lille, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France
| | - D Staumont-Sallé
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, CHU Lille, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France
| | - B Milpied
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, UHC Bordeaux, Bordeaux, France
| | - F Tetart
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, UHC Rouen, Rouen, France
| | - N de Prost
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Intensive Care Unit, AP-HP, Henri-Mondor Hospital, Créteil, France
| | - S Fourati
- Virology Department, AP-HP, Henri-Mondor Hospital, Créteil, France
| | - N Ortonne
- Department of Pathology, Henri-Mondor Hospital, Créteil, France
| | - F Kasimir
- Institute for Virology and Immunobiology, Julius-Maximilians-UniversitätWürzburg, Würzburg, Germany
| | - B K Prusty
- Institute for Virology and Immunobiology, Julius-Maximilians-UniversitätWürzburg, Würzburg, Germany
| | - V Descamps
- Department of Dermatology, AP-HP, Bichat Hospital, Paris, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
| |
Collapse
|
17
|
Cohen E, Lheure C, Ingen-Housz-Oro S, Hotz C, Bettuzzi T, Chasset F, Descamps V, Deschamps L, Mahevas M, Terrier B, Sohier P, Guegan S, Kramkimel N, Darbord D, Chanal J, Oulès B, Aractingi S, Seta V, Dupin N. Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients. Eur J Dermatol 2023; 33:680-685. [PMID: 38465550 DOI: 10.1684/ejd.2023.4584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.
Collapse
Affiliation(s)
- Elisabeth Cohen
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Coralie Lheure
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, APHP, Mondor Hospital, Paris, France, EpiDermE, University Paris Est Créteil, Créteil, France
| | - Claire Hotz
- Department of Dermatology, APHP, Mondor Hospital, Paris, France
| | - Thomas Bettuzzi
- Department of Dermatology, APHP, Mondor Hospital, Paris, France
| | | | | | - Lydia Deschamps
- Department of Pathology, APHP, Bichat Hospital, Paris, France
| | - Matthieu Mahevas
- Department of Internal Medicine, APHP, Mondor Hospital, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, APHP, Cochin Hospital, Paris, France
| | - Pierre Sohier
- Department of Pathology, APHP, Cochin Hospital, Paris, France
| | - Sarah Guegan
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Nora Kramkimel
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | | | - Johan Chanal
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Benedicte Oulès
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Selim Aractingi
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Vannina Seta
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Nicolas Dupin
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| |
Collapse
|
18
|
Demouche S, Bettuzzi T, Sbidian E, Laugier Castellan D, Osmont MN, Ingen-Housz-Oro S, Lebrun-Vignes B. Reality of drug-induced erythema multiforme: A French pharmacovigilance study. Therapie 2023; 78:711-719. [PMID: 37024401 DOI: 10.1016/j.therap.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 02/08/2023] [Accepted: 03/02/2023] [Indexed: 03/11/2023]
Abstract
BACKGROUND Since the 2002 SCAR study, erythema multiforme (EM), a post-infectious disease, has been distinguished from Stevens-Johnson syndrome (SJS), drug-induced. Nevertheless, EM cases are still reported in the French pharmacovigilance database (FPDB). OBJECTIVES To describe EM reported in the FPDB and to compare the quality and the characteristics of the reports. METHODS This retrospective observational study selected all EM cases reported in the FPDB over two periods: period 1 (P1, 2008-2009) and period 2 (P2, 2018-2019). Inclusion criteria were 1) a diagnosis of clinically typical EM and/or validated by a dermatologist; 2) a reported date of onset of the reaction; and 3) a precise chronology of drug exposure. Cases were classified confirmed EM (typical acral target lesions and/or validation by a dermatologist) and possible EM (not-otherwise-specified target lesions, isolated mucosal involvement, doubtful with SJS). We concluded possible drug-induced EM when EM was confirmed, with onset ranging from 5 to 28 days without an alternative cause. RESULTS Among 182 selected reports, 140 (77%) were analyzed. Of these, 67 (48%) presented a more likely alternative diagnosis than EM. Of the 73 reports of EM cases finally included (P1, n=41; P2, n=32), 36 (49%) had a probable non-drug cause and 28 (38%) were associated with only drugs with an onset time ≤4 days and/or ≥29 days. Possible drug-induced EM was retained in 9 cases (6% of evaluable reports). Etiological work-up was more often performed in period 2 than 1 (53.1% vs 29.3%, P=0.04), and the time to onset from 5 to 28 days was more frequent in period 2 (59.2% vs 40%, P=0.04). CONCLUSIONS This study suggests that possible drug-induced EM is rare. Many reports describe "polymorphic" rashes inappropriately concluded as EM or post-infectious EM with unsuitable drug accountability subject to protopathic bias.
Collapse
Affiliation(s)
- Sarah Demouche
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France
| | - Thomas Bettuzzi
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Université Paris-Est Créteil, EpiDermE, 94000 Créteil, France
| | - Emilie Sbidian
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Université Paris-Est Créteil, EpiDermE, 94000 Créteil, France
| | - Delphine Laugier Castellan
- Centre régional de pharmacovigilance Marseille - Provence - Corse, hôpital Sainte-Marguerite, AP-HM, 13005 Marseille, France
| | - Marie-Noelle Osmont
- Centre régional de pharmacovigilance de Rennes, CHRU hôpital Pontchaillou, 35000 Rennes, France
| | - Saskia Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Université Paris-Est Créteil, EpiDermE, 94000 Créteil, France; Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, 94000 Créteil, France.
| | - Bénédicte Lebrun-Vignes
- Université Paris-Est Créteil, EpiDermE, 94000 Créteil, France; Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, 94000 Créteil, France; Centre régional de Pharmacovigilance - hôpital Pitié-Salpêtrière GH, Sorbonne université, AP-HP, 75000 Paris, France
| |
Collapse
|
19
|
Abstract
Bullous pemphigoid affects people who are usually very frail, because they are very old and frequently have neurological co-morbidities. Over the past twenty years, therapeutic management has improved thanks to the application of highly potent corticosteroid-based creams, following a well-established regimen, for several months. Well-conducted nursing care is therefore essential not only to cover wounds, but also to treat the disease. Dedicated nursing time is also an opportunity to provide support to patients, who are often very uncomfortable.
Collapse
Affiliation(s)
- Christelle Le Roux-Villet
- Service de dermatologie, centre de référence des maladies bulleuses auto-immunes, hôpital Avicenne, AP-HP, 93009 Bobigny cedex, France.
| | - Ingrid Hurtel
- Service de dermatologie, centre de référence des maladies bulleuses auto-immunes, hôpital Avicenne, AP-HP, 93009 Bobigny cedex, France
| | - Céline Lastiri
- Service de dermatologie, centre de référence des maladies bulleuses auto-immunes, hôpital Avicenne, AP-HP, 93009 Bobigny cedex, France
| | - Saskia Ingen-Housz-Oro
- Service de dermatologie, centre de compétence Maladies Bulleuses Auto-Immunes, Hôpital Henri Mondor, 1 rue Gustave Eiffel, 94000 Créteil, France
| | - Sophie Duvert-Lehembre
- Service de dermatologie, centre hospitalier de Dunkerque, 103 avenue Louis-Herbeaux, 59385 Dunkerque, France; Service de dermatologie, centre de compétence maladies bulleuses auto-immunes, hôpital Claude- Huriez, rue Michel-Polonowski, 59037 Lille, France
| |
Collapse
|
20
|
Welfringer-Morin A, Bataille P, Drummond D, Bellon N, Ingen-Housz-Oro S, Bonigen J, Schmartz S, Giraud-Kerleroux L, Moulin F, De Saint Blanquat L, Bremond-Gignac D, Hadj-Rabia S, Bodemer C. Comparison of idiopathic and drug-induced epidermal necrolysis in children. Br J Dermatol 2023; 189:631-633. [PMID: 37410549 DOI: 10.1093/bjd/ljad226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 06/30/2023] [Accepted: 08/05/2023] [Indexed: 07/08/2023]
Abstract
In this monocentric retrospective study in a French paediatric reference centre, children with idiopathic epidermal necrolysis (EN) had more severe disease than those with drug-induced EN during the acute stage. In our study, no EN was attributed to infection.
Collapse
Affiliation(s)
- Anne Welfringer-Morin
- Department of Paediatric Dermatology
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Paris, France
| | | | | | - Nathalia Bellon
- Department of Paediatric Dermatology
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Paris, France
| | - Saskia Ingen-Housz-Oro
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Paris, France
- Department of Dermatology, AP-HP, Henri Mondor Hospital, University Paris-Est Créteil EpidermE, Créteil, France
| | - Julie Bonigen
- Paediatric Intensive Care Unit, Necker-Enfants Malades Hospital, University Paris Cité, AP-HP, France
| | | | - Laura Giraud-Kerleroux
- Department of Dermatology, AP-HP, Henri Mondor Hospital, University Paris-Est Créteil EpidermE, Créteil, France
| | - Florence Moulin
- Paediatric Intensive Care Unit, Necker-Enfants Malades Hospital, University Paris Cité, AP-HP, France
| | - Laure De Saint Blanquat
- Paediatric Intensive Care Unit, Necker-Enfants Malades Hospital, University Paris Cité, AP-HP, France
| | - Dominique Bremond-Gignac
- Department of Ophthalmology, Necker-Enfants Malades Hospital, University Paris Cité, AP-HP, Paris, France
| | | | - Christine Bodemer
- Department of Paediatric Dermatology
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Paris, France
| |
Collapse
|
21
|
Ingen-Housz-Oro S. Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure. Br J Dermatol 2023; 189:505-506. [PMID: 37493194 DOI: 10.1093/bjd/ljad254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 07/19/2023] [Indexed: 07/27/2023]
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions, TOXIBUL, Créteil; ToxiTEN group of the ERN-skin, Paris; Univ Paris Est Créteil EpiDermE, Créteil, France
| |
Collapse
|
22
|
Hama N, Sunaga Y, Ochiai H, Kokaze A, Watanabe H, Kurosawa M, Azukizawa H, Asada H, Watanabe Y, Yamaguchi Y, Aihara M, Mizukawa Y, Ohyama M, Hashizume H, Nakajima S, Nomura T, Kabashima K, Tohyama M, Hasegawa A, Takahashi H, Mieno H, Ueta M, Sotozono C, Niihara H, Morita E, Brüggen MC, Feingold IM, Jeschke MG, Dodiuk-Gad RP, Oppel EM, French LE, Chen WT, Chung WH, Chu CY, Kang HR, Ingen-Housz-Oro S, Nakamura K, Sueki H, Abe R. Development and Validation of a Novel Score to Predict Mortality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: CRISTEN. J Allergy Clin Immunol Pract 2023; 11:3161-3168.e2. [PMID: 37429419 DOI: 10.1016/j.jaip.2023.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 06/13/2023] [Accepted: 07/02/2023] [Indexed: 07/12/2023]
Abstract
BACKGROUND Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening, severe mucocutaneous adverse reactions. Severity prediction at early onset is urgently required for treatment. However, previous prediction scores have been based on data of blood tests. OBJECTIVE This study aimed to present a novel score that predicts mortality in patients with SJS/TEN in the early stages based on only clinical information. METHODS We retrospectively evaluated 382 patients with SJS/TEN in a development study. A clinical risk score for TEN (CRISTEN) was created according to the association of potential risk factors with death. We calculated the sum of these risk factors using CRISTEN, and this was validated in a multinational survey of 416 patients and was compared with previous scoring systems. RESULTS The significant risk factors for death in SJS/TEN comprised 10 items, including patients' age of ≥65 years, ≥10% body surface area involvement, the use of antibiotics as culprit drugs, the use of systemic corticosteroid therapy before the onset, and mucosal damage affecting the ocular, buccal, and genital mucosa. Renal impairment, diabetes, cardiovascular disease, malignant neoplasm, and bacterial infection were included as underlying diseases. The CRISTEN model showed good discrimination (area under the curve [AUC] = 0.884) and calibration. In the validation study, the AUC was 0.827, which was statistically comparable to those of previous systems. CONCLUSION A scoring system based on only clinical information was developed to predict mortality in SJS/TEN and was validated in an independent multinational study. CRISTEN may predict individual survival probabilities and direct the management and therapy of patients with SJS/TEN.
Collapse
Affiliation(s)
- Natsumi Hama
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Yuma Sunaga
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan; Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hirotaka Ochiai
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Akatsuki Kokaze
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hideaki Watanabe
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Michiko Kurosawa
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine, Tokyo, Japan
| | | | - Hideo Asada
- Department of Dermatology, Nara Medical University, Nara, Japan
| | - Yuko Watanabe
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Yukie Yamaguchi
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Michiko Aihara
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Yoshiko Mizukawa
- Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan
| | - Manabu Ohyama
- Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan
| | - Hideo Hashizume
- Department of Dermatology, Iwata City Hospital, Shizuoka, Japan
| | - Saeko Nakajima
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takashi Nomura
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Kenji Kabashima
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Mikiko Tohyama
- Department of Dermatology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - Akito Hasegawa
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Hayato Takahashi
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - Hiroki Mieno
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Mayumi Ueta
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Chie Sotozono
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Hiroyuki Niihara
- Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Eishin Morita
- Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Marie-Charlotte Brüggen
- Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland; Christine Kühne Foundation for Allergy Research and Education (CK Care), Davos, Switzerland
| | | | - Marc G Jeschke
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Roni P Dodiuk-Gad
- Technion-Israel Institute of Technology, Haifa, Israel; Department of Dermatology, Emek Medical Center, Afula, Israel; Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Department of Medicine, University of Toronto, Ontario, Canada
| | - Eva Maria Oppel
- Department of Dermatology and Allergy, University Hospital, LMU, Munich, Germany
| | - Lars E French
- Department of Dermatology and Allergy, University Hospital, LMU, Munich, Germany; Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Fla
| | - Wei-Ti Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Linkou, Taipei, Taiwan
| | - Wen-Hung Chung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Linkou, Taipei, Taiwan
| | - Chia-Yu Chu
- Department of Dermatology, National Taiwan University Hospital and National Taiwan College of Medicine, Taipei, Taiwan
| | - Hye-Ryun Kang
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France; Univ Paris Est Créteil EpidermE, Créteil, France; Reference Center for Toxic Bullous Diseases TOXIBUL, Créteil, France
| | - Kazutoshi Nakamura
- Division of Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Hirohiko Sueki
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Riichiro Abe
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
| |
Collapse
|
23
|
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet 2023; 401:1941-1950. [PMID: 37105210 DOI: 10.1016/s0140-6736(23)00329-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 01/26/2023] [Accepted: 02/10/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs. METHODS In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting. FINDINGS From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group. INTERPRETATION Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission. FUNDING French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.
Collapse
Affiliation(s)
- Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.
| | - Marie Beylot-Barry
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Baptiste Mear
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Stéphane Dalle
- Department of Dermatology, Hôpital Lyon-Sud, Lyon, France
| | - Michel d'Incan
- Department of Dermatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France
| | - Corentin Orvain
- Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France; Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, Angers, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1307, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6075, Nantes Université, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université d'Angers, Angers, France
| | - Julie Abraham
- Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - Olivier Dereure
- Department of Dermatology and Institut National de la Santé et de la Recherche Médicale U1058 Pathogenesis and Control of Chronic and Emergent Infections, University of Montpellier, Montpellier, France
| | - Amandine Charbonnier
- Department of Hematology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Jérôme Cornillon
- Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
| | - Christine Longvert
- Department of Dermatology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Stéphane Barete
- Department of Dermatology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Serge Boulinguez
- Department of Dermatology, Centre Hospitalier Universitaire Toulouse, Toulouse, France
| | - Ewa Wierzbicka-Hainaut
- Department of Dermatology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - François Aubin
- Department of Dermatology, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Marie-Thérèse Rubio
- Department of Hematology, Hôpital Brabois, Centre Hospitalier Régional Universitaire Nancy, Nancy, France; Centre National de la Recherche Scientifique Unité Mixte de Recherche 7365, Ingéniérie Moléculaire et Physiopathologie Articulaire, Biopole, University of Lorraine, Nancy, France
| | - Marc Bernard
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Aline Schmidt-Tanguy
- Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Roch Houot
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France; Institut National de la Santé et de la Recherche Médicale U1236, Rennes, France
| | - Anne Pham-Ledard
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France
| | - David Michonneau
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Pauline Brice
- Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Florent Grange
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | - Hélène Moins-Teisserenc
- Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France
| | - Katayoun Jondeau
- Department of Hematology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Laurence Michel
- Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Samia Mourah
- Department of Tumor Genomics and Pharmacology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Maxime Battistella
- Pathology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Etienne Daguindau
- Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Michael Loschi
- Department of Hematology, Hôpital L'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Alexandra Picard
- Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Nathalie Franck
- Department of Dermatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Natacha Maillard
- Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Anne Huynh
- Department of Hematology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Stéphanie Nguyen
- Department of Hematology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ambroise Marçais
- Department of Hematology, Centre Hospitalier Universitaire Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Guillaume Chaby
- Department of Dermatology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Patrice Ceballos
- Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Yannick Le Corre
- Department of Dermatology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Sébastien Maury
- Department of Hematology, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Jacques-Olivier Bay
- Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Henri Adamski
- Department of Dermatology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Emmanuel Bachy
- Department of Hematology, Centre Hospitalier Universitaire de Lyon, Lyon, France
| | - Edouard Forcade
- Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Gérard Socié
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Sylvie Chevret
- Department of Biostatistics, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France; Institut National de la Santé et de la Recherche Médicale U1153, Paris, France
| | - Régis Peffault de Latour
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France.
| |
Collapse
|
24
|
Moghadam P, Tancrede E, Bouaziz JD, Kallout J, Bedane C, Begon E, Bourgault-Villada I, Calugareanu A, Dereure O, Jendoubi F, Pham-Ledard A, Ingen-Housz-Oro S, Picard-Dahan C, Viguier M, Mahevas T, Jachiet M, Charvet E, Cassius C, Alexandre M, Lepelletier C. Efficacity and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients. Br J Dermatol 2023:7157001. [PMID: 37155583 DOI: 10.1093/bjd/ljad136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Revised: 03/30/2023] [Accepted: 04/25/2023] [Indexed: 05/10/2023]
Abstract
Bullous pemphigoid (BP) is the most common auto immune blistering disease in Europe and its treatment can be challenging. Several published cases reported dupilumab efficiency in refractory patients. We conducted a retrospective multicentric study including 36 patients to evaluate real-life efficiency of dupilumab in BP. Our results suggest that dupilumab in association with high potency topical steroids could be rapidly effective in various clinical forms of BP and seems to be well tolerated in elderly population.
Collapse
Affiliation(s)
- Parna Moghadam
- Dermatology Department, Saint-Louis Hospital, Paris, France
| | | | | | | | | | - Edouard Begon
- Dermatology Department, René Dubos Hospital, Pontoise, France
| | | | | | | | | | | | - Saskia Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, Univ Paris Est Créteil EpidermE, Créteil, France
| | | | - Manuelle Viguier
- Dermatology Department, National Reference Center for Auto-immune Blistering Diseases, Robert Debré Hospital, Université Reims-Champagne Ardenne, EA 7509 IRMAIC, Reims, France
| | | | - Marie Jachiet
- Dermatology Department, Saint-Louis Hospital, Paris, France
| | | | | | | | | |
Collapse
|
25
|
Ingen-Housz-Oro S, Milpied B, Bensaid B, Elshot Y, Brüggen MC, Starace M, Kaffenberger BH, Carrera C, Pham-Ledard A, Freites-Martinez A, Sanchez-Pena P, Lebrun-Vignes B, French LE, Sibaud V. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases. Melanoma Res 2023; 33:155-158. [PMID: 36749114 DOI: 10.1097/cmr.0000000000000877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), drug reactions with eosinophilia and systemic symptoms (DRESS) have been very rarely reported. The objective of this study is to better define the clinical and histologic features, treatment and prognosis of ICI-related DRESS. This retrospective case series was conducted between 01 January 2015 and 31 December 2021 by the dermatology departments of five international networks involved in drug reactions. Inclusion criteria were age ≥18 years old, DRESS with Regiscar score ≥4 (probable or certain) and ICI as a suspect drug. Clinical, biologic and follow-up data were extracted from the medical charts. Thirteen patients were included. The median time to onset was 22 days (3-11). No patients had a high-risk drug introduced in the past 3 months. A majority of patients presented fever (92%), diffuse exanthema (77%) and facial edema (69%). Biologic features included hypereosinophilia in eight patients (61.5%), hyperlymphocytosis in 3 (23%), elevated liver function tests in 11 (85%, grade 1 or 2 in most cases) and renal involvement in 5 (38%). Two patients (15%) had lung involvement. PCR evidence of viral replication was detected in five patients (38.5%). Treatment involved discontinuation of the suspect ICI and systemic steroids with variable dose and duration regimens. Among the four patients in which ipilimumab + nivolumab combination therapy was initially suspected, one was rechallenged with nivolumab monotherapy with good tolerance. Five patients were switched to another anti-PD-1 plus low-dose systemic steroids, with good tolerance in four cases. No patient died because of DRESS. DRESS induced by ICI are rare and of moderate severity. A consensus for management is still pending.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil
- FISARD group, Paris
- University Paris est Créteil EpidermE, Créteil, France
- EADV European Task Force 'Dermatology for cancer patients'
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris
| | - Brigitte Milpied
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil
- FISARD group, Paris
- EADV European Task Force 'Dermatology for cancer patients'
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris
- Dermatology Department, CHU Bordeaux, Bordeaux
| | - Benoit Bensaid
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil
- FISARD group, Paris
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris
- Dermatology Department, CHU Edouard Herriot, Lyon, France
| | - Yannick Elshot
- EADV European Task Force 'Dermatology for cancer patients'
- Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Marie Charlotte Brüggen
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris
- Department of Dermatology, University Hospital Zurich
- Faculty of Medicine, University Zurich, Zurich
- Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
| | - Michela Starace
- EADV European Task Force 'Dermatology for cancer patients'
- Dermatology -IRCCS Policlinico di Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Italy
| | - Benjamin H Kaffenberger
- EADV European Task Force 'Dermatology for cancer patients'
- Dermatology Department, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Cristina Carrera
- EADV European Task Force 'Dermatology for cancer patients'
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona
- CIBERER Centro de investigaciones Biomedicas en Red de Enfermedades Raras Insituto de Salud Carlos III
- Pharmacovigilance Technical Committee Hospital Clinic Barcelona
| | | | - Azael Freites-Martinez
- EADV European Task Force 'Dermatology for cancer patients'
- Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain
| | - Paola Sanchez-Pena
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil
- FISARD group, Paris
- Pharmacovigilance Department, CHU Bordeaux, Bordeaux
| | - Bénédicte Lebrun-Vignes
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil
- FISARD group, Paris
- Pharmacovigilance Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Lars E French
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris
- Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan University (LMU) Munich, Munich, Germany
- Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - Vincent Sibaud
- EADV European Task Force 'Dermatology for cancer patients'
- Department of Oncodermatology, Claudius Regaud Institute and University Cancer Institute Toulouse Oncopole, Toulouse, France
| |
Collapse
|
26
|
Ahouach B, Diaz E, Bertin B, Ben Said B, Combret S, Grandvuillemin A, Petitpain N, Rabier MB, Thomas L, Trenque T, Ingen-Housz-Oro S, Lebrun-Vignes B. Epidermal necrolysis after COVID-19 vaccination: An exploratory analysis using World Health Organization VigiBase. J Eur Acad Dermatol Venereol 2023; 37:e456-e459. [PMID: 36606525 DOI: 10.1111/jdv.18845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 12/13/2022] [Indexed: 01/07/2023]
Affiliation(s)
- Btisseme Ahouach
- Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France
| | - Emmanuelle Diaz
- Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France
| | - Blandine Bertin
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon HCL, Lyon, France
| | - Benoit Ben Said
- Dermatology Department, Edouard Herriot Hospital, Lyon, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Sandrine Combret
- Pharmacovigilance Department, Dijon University Hospital, Dijon, France
| | | | - Nadine Petitpain
- Pharmacovigilance Department, Nancy-Brabois Hospital, Vandoeuvre-lès-Nancy, France
| | | | - Laure Thomas
- Pharmacovigilance Department, Henri-Mondor Hospital AP-HP, Créteil, France
| | - Thierry Trenque
- Pharmacovigilance Department, University Hospitals of Reims, Reims, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris Est Créteil Epiderme, UPEC, Créteil, France
| | - Bénédicte Lebrun-Vignes
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris Est Créteil Epiderme, UPEC, Créteil, France.,Pharmacovigilance Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France
| |
Collapse
|
27
|
Kridin K, Brüggen MC, Walsh S, Bensaid B, Ranki A, Oppel E, Meyersburg D, Chua SL, Seeli C, Sandberg H, French LE, Vorobyev A, Ingen-Housz-Oro S. Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases. J Eur Acad Dermatol Venereol 2023; 37:753-762. [PMID: 36479739 DOI: 10.1111/jdv.18808] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 11/29/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. OBJECTIVE To explore treatment approaches across Europe and their impact on the disease course, as well as prognostic factors and culprit drugs. METHODS In this retrospective European multicentric study, we included patients with probable or certain DRESS (RegiSCAR score ≥ 4) between January 2016 and December 2020. Independent associations between clinical parameters and the risk of intensive care unit admission and mortality at three months were assessed using a multivariable-adjusted logistic regression model. RESULTS A total of 141 patients from 8 tertiary centres were included. Morbilliform exanthem was the most frequent cutaneous manifestation (78.0%). The mean affected body surface area (BSA) was 67%, 42% of the patients presented with erythroderma, and 24.8% had mucosal involvement. Based on systemic involvement, 31.9% of the patients had a severe DRESS. Anticonvulsants (24.1%) and sulphonamides (22.0%) were the most frequent causative agents. In all, 73% of the patients were treated with systemic glucocorticoids, and 25.5% received topical corticosteroids as monotherapy. Few patients received antiviral drugs or anti-IL5. No patients received intravenous immunoglobulins. The overall mortality was 7.1%. Independent predictors of mortality were older age (≥57.0 years; fully adjusted OR, 9.80; 95% CI, 1.20-79.93; p = 0.033), kidney involvement (fully adjusted OR, 4.70; 95% CI, 1.00-24.12; p = 0.049), and admission in intensive care unit (fully adjusted OR, 8.12; 95% CI, 1.90-34.67; p = 0.005). Relapse of DRESS and delayed autoimmune sequelae occurred in 8.5% and 12.1% of patients, respectively. CONCLUSIONS This study underlines the need for diagnostic and prognostic scores/markers as well as for prospective clinical trials of drugs with the potential to reduce mortality and complications of DRESS.
Collapse
Affiliation(s)
- Khalaf Kridin
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.,Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
| | - Marie-Charlotte Brüggen
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.,Faculty of Medicine, University of Zurich, Zurich, Switzerland.,Medical Campus Davos, Davos, Switzerland.,ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin)
| | - Sarah Walsh
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Department of Dermatology, King's College Hospital, London, UK
| | - Benoit Bensaid
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Department of Dermatology, Edouard Herriot Hospital, Lyon, France
| | - Annamari Ranki
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Department of Dermatology, Allergology and Venereology, University of Helsinki and Helsinki University Hospital, Inflammation Center, Helsinki, Finland
| | - Eva Oppel
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany
| | - Damian Meyersburg
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg, Salzburg, Austria
| | - Ser-Ling Chua
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - Corsin Seeli
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - Heidi Sandberg
- Department of Dermatology, Allergology and Venereology, University of Helsinki and Helsinki University Hospital, Inflammation Center, Helsinki, Finland
| | - Lars E French
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany.,Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA
| | - Artem Vorobyev
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.,ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Department of Dermatology, University Medical Center Schleswig-Holstein, Lübeck, Germany
| | - Saskia Ingen-Housz-Oro
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-Skin).,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Univ Paris Est Créteil EpiDermE, Créteil, France
| |
Collapse
|
28
|
Thorel D, Ingen-Housz-Oro S, Benaïm D, Daien V, Gabison E, Saunier V, Béral L, Touboul D, Brémond-Gignac D, Robert M, Vasseur R, Royer G, Dereure O, Milpied B, Bernier C, Welfringer-Morin A, Bodemer C, Cordel N, Tauber M, Burillon C, Servant M, Couret C, Vabres B, Tétart F, Cassagne M, Kuoch MA, Muraine M, Delcampe A, Gueudry J. Ocular sequelae of epidermal necrolysis: French national audit of practices, literature review and proposed management. Orphanet J Rare Dis 2023; 18:51. [PMID: 36906580 PMCID: PMC10007779 DOI: 10.1186/s13023-023-02616-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Accepted: 01/15/2023] [Indexed: 03/13/2023] Open
Abstract
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and rare diseases, most often drug-induced, and their incidence has been estimated at 6 cases/million/year in France. SJS and TEN belong to the same spectrum of disease known as epidermal necrolysis (EN). They are characterized by more or less extensive epidermal detachment, associated with mucous membrane involvement, and may be complicated during the acute phase by fatal multiorgan failure. SJS and TEN can lead to severe ophthalmologic sequelae. There are no recommendations for ocular management during the chronic phase. We conducted a national audit of current practice in the 11 sites of the French reference center for toxic bullous dermatoses and a review of the literature to establish therapeutic consensus guidelines. Ophthalmologists and dermatologists from the French reference center for epidermal necrolysis were asked to complete a questionnaire on management practices in the chronic phase of SJS/TEN. The survey focused on the presence of a referent ophthalmologist at the center, the use of local treatments (artificial tears, corticosteroid eye drops, antibiotic-corticosteroids, antiseptics, vitamin A ointment (VA), cyclosporine, tacrolimus), the management of trichiatic eyelashes, meibomian dysfunction, symblepharons, and corneal neovascularization, as well as the contactologic solutions implemented. Eleven ophthalmologists and 9 dermatologists from 9 of the 11 centers responded to the questionnaire. Based on questionnaire results, 10/11 ophthalmologists systematically prescribed preservative-free artificial tears, and 11/11 administered VA. Antiseptic or antibiotic eye drops or antibiotic-corticosteroid eye drops were recommended as needed by 8/11 and 7/11 ophthalmologists, respectively. In case of chronic inflammation, topical cyclosporine was consistently proposed by 11/11 ophthalmologists. The removal of trichiatic eyelashes was mainly performed by 10/11 ophthalmologists. Patients were referred to a reference center for fitting of scleral lenses (10/10,100%). Based on this practice audit and literature review, we propose an evaluation form to facilitate ophthalmic data collection in the chronic phase of EN and we also propose an algorithm for the ophthalmologic management of ocular sequelae.
Collapse
Affiliation(s)
- Dhyna Thorel
- Ophthalmology Department, CHU Charles Nicolle Rouen, Rouen, France.
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
| | - Saskia Ingen-Housz-Oro
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, AP-HP, Henri Mondor Hospital, Univ Paris Est Créteil EpidermE, Créteil, France
| | - Daniel Benaïm
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Vincent Daien
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department CHU Montpellier, Montpellier, France
| | - Eric Gabison
- 6Ophthalmology Department, Hôpital Fondation Adolphe de Rothschild, Paris, France
| | - Valentine Saunier
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU Bordeaux, Bordeaux, France
| | - Laurence Béral
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU Pointe À Pitre, Pointe À Pitre, Guadeloupe, France
| | - David Touboul
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU Bordeaux, Bordeaux, France
| | - Dominique Brémond-Gignac
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, Hôpital Universitaire Necker Enfants-Malades, APHP, Paris, France
| | - Matthieu Robert
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, Hôpital Universitaire Necker Enfants-Malades, APHP, Paris, France
| | - Robin Vasseur
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU de Nantes, Nantes, France
| | - Gérard Royer
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Olivier Dereure
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, CHU Montpellier, Montpellier, France
| | - Brigitte Milpied
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - Claire Bernier
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, CHU Nantes, Nantes, France
| | - Anne Welfringer-Morin
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, AP-HP, Hôpital Universitaire Necker Enfants-Malades, APHP, Paris, France
| | - Christine Bodemer
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, AP-HP, Hôpital Universitaire Necker Enfants-Malades, APHP, Paris, France
| | - Nadège Cordel
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology and Clinical Immunology Department, CHU Guadeloupe, Pointe À Pitre, , Guadeloupe, France
| | - Marie Tauber
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Dermatology Department, CHU de Toulouse, Toulouse, France
| | - Carole Burillon
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmolgy Department, CHU Lyon, Lyon, France
| | - Marion Servant
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU de Nantes, Nantes, France
| | - Chloe Couret
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU de Nantes, Nantes, France
| | - Bertrand Vabres
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU de Nantes, Nantes, France
| | - Florence Tétart
- Ophthalmology Department, CHU Charles Nicolle Rouen, Rouen, France
- Dermatology Department, CHU Charles Nicolle Rouen, Rouen, France
| | - Myriam Cassagne
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, CHU de Toulouse, Toulouse, France
| | - Marie-Ange Kuoch
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Ophthalmology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Marc Muraine
- Ophthalmology Department, CHU Charles Nicolle Rouen, Rouen, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Agnès Delcampe
- Ophthalmology Department, CHU Charles Nicolle Rouen, Rouen, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Julie Gueudry
- Ophthalmology Department, CHU Charles Nicolle Rouen, Rouen, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
29
|
Ingen-Housz-Oro S. [Identification of cutaneous adverse drug reactions]. Rev Prat 2023; 73:307-313. [PMID: 37289124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
IDENTIFICATION OF CUTANEOUS ADVERSE DRUG REACTIONS. Cutaneous adverse drug reactions are common. The most common are maculopapular exanthemas, which heal within a few days. However, clinical and biological signs of severity should be ruled out. Severe drug reactions include acute generalized exanthematous pustulosis, DRESS (drug reaction with eosinophilia and systemic symptoms), and epidermal necrolysis (Stevens-Johnson and Lyell syndromes). The search for the suspect drug is based on the questioning of the patient or his entourage and a chronological timeline. The treatment of drug eruption depends on its nosological type and the patient's background. For any severe drug reaction, hospitalization in a specialized units is necessary. Follow-up of epidermal necrolysis should be prolonged due to the frequency of disabling sequelae. All drug reactions, in particular the severe forms, must be declared to the pharmacovigilance services.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, Créteil, France ; centre de référence des dermatoses bulleuses toxiques et toxidermies graves, TOXIBUL, Créteil, France ; unité EpidermE, université Paris-Est Créteil, Créteil, France
| |
Collapse
|
30
|
Fredeau L, Courvoisier DS, Ait Mehdi R, Ingen-Housz-Oro S, Mahe E, Costedoat-Chalumeau N, Arnaud L, Francès C, Mathian A, Jachiet M, Amoura Z, Bouaziz JD, Chasset F. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol 2023; 88:551-559. [PMID: 36156304 DOI: 10.1016/j.jaad.2022.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Revised: 08/29/2022] [Accepted: 09/10/2022] [Indexed: 12/31/2022]
Abstract
BACKGROUND No study has assessed the risk factors of progression from discoid lupus erythematosus (DLE) to severe systemic lupus erythematosus (sSLE) (defined as requiring hospitalization and specific treatment). OBJECTIVE To identify the risks factors of and generate a predicting score for progression to sSLE among patients with isolated DLE or associated with systemic lupus erythematosus with mild biological abnormalities. METHODS In this registry-based cohort study, multivariable analysis was performed using risk factors identified from literature and pruned by backward selection to identify relevant variables. The number of points was weighted proportionally to the odds ratio (OR). RESULTS We included 30 patients with DLE who developed sSLE and 134 patients who did not. In multivariable analysis, among 12 selected variables, an age of <25 years at the time of DLE diagnosis (OR, 2.8; 95% CI, 1.1-7.0; 1 point), phototype V to VI (OR, 2.7; 95% CI, 1.1-7.0; 1 point), and antinuclear antibody titers of ≥1:320 (OR, 15; 95% CI, 3.3-67.3; 5 points) were selected to generate the score. Among the 54 patients with a score of 0 at baseline, none progressed to sSLE, whereas a score of ≥6 was associated with a risk of approximately 40%. LIMITATIONS Retrospective design. CONCLUSION In our cohort, an age of <25 years at the time of DLE diagnosis, phototype V to VI, and antinuclear antibody titers of ≥1:320 were risk factors for developing sSLE.
Collapse
Affiliation(s)
- Lisa Fredeau
- Sorbonne Université, Faculté de médecine, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France
| | - Delphine S Courvoisier
- Service d'Épidémiologie Clinique, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Raphael Ait Mehdi
- Service de dermatologie, Grand Hôpital de l'Est Francilien, Jossigny, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, AP-HP, Hôpital Mondor, Univ Paris Est Créteil EpidermE, Créteil, France
| | - Emmanuel Mahe
- Service de dermatologie, Centre hospitalier Victor Dupuy, Argenteuil, France
| | | | - Laurent Arnaud
- Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Centre National de Références des Maladies Systémiques et Autoimmunes Rares Est Sud-Ouest (RESO), Université de Strasbourg, Strasbourg, France
| | - Camille Francès
- Sorbonne Université, Faculté de médecine, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France
| | - Alexis Mathian
- Sorbonne université, Faculté de médecine, AP-HP, Groupement Hospitalier Pitié-Salpêtrière, Centre national de référence du lupus systémique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de Médecine Interne 2, Institut E3M, Paris, France
| | - Marie Jachiet
- Université de Paris, Faculté de Médecine, AH-HP, Service de Dermatologie, Hôpital Saint-Louis, Paris, France
| | - Zahir Amoura
- Sorbonne université, Faculté de médecine, AP-HP, Groupement Hospitalier Pitié-Salpêtrière, Centre national de référence du lupus systémique, du syndrome des antiphospholipides et autres maladies auto-immunes, Service de Médecine Interne 2, Institut E3M, Paris, France
| | - Jean David Bouaziz
- Université de Paris, Faculté de Médecine, AH-HP, Service de Dermatologie, Hôpital Saint-Louis, Paris, France
| | - François Chasset
- Sorbonne Université, Faculté de médecine, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France.
| |
Collapse
|
31
|
Ingen-Housz-Oro S, Bettuzzi T, Badaoui B, de Prost N. Outcomes Associated With Neutropenia and Lymphopenia in Epidermal Necrolysis: A Single-Center Retrospective Study of 147 Patients. JAMA Dermatol 2023; 159:338-340. [PMID: 36753188 PMCID: PMC9909568 DOI: 10.1001/jamadermatol.2022.6262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 12/06/2022] [Indexed: 02/09/2023]
Abstract
This retrospective cohort study examines the association of lymphocyte and neutrophil levels with treatment outcomes in 147 patients with epidermal necrolysis in France.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Service de dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Université Paris Est Créteil EpidermE, Créteil, France
- Reference Center of Toxic bullous Diseases and severe drug reactions TOXIBUL, Créteil, France
| | - Thomas Bettuzzi
- Service de dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Université Paris Est Créteil EpidermE, Créteil, France
- Reference Center of Toxic bullous Diseases and severe drug reactions TOXIBUL, Créteil, France
| | - Bouchra Badaoui
- Département d’Hématologie et Immunologie biologiques, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Nicolas de Prost
- Université Paris Est Créteil EpidermE, Créteil, France
- Reference Center of Toxic bullous Diseases and severe drug reactions TOXIBUL, Créteil, France
- Service de médecine intensive réanimation, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| |
Collapse
|
32
|
Bettuzzi T, Lalevée S, Badaoui B, Hua C, Wolkenstein P, de Prost N, Ingen-Housz-Oro S. Novel inflammatory markers and in-hospital mortality in epidermal necrolysis-A monocentric study of 137 patients. J Eur Acad Dermatol Venereol 2023; 37:e382-e383. [PMID: 36149304 DOI: 10.1111/jdv.18578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 09/01/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Thomas Bettuzzi
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EpiDermE, Univ Paris Est Créteil Val de Marne, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Sophie Lalevée
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Bouchra Badaoui
- Service d'Hématologie biologique, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Camille Hua
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EpiDermE, Univ Paris Est Créteil Val de Marne, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Pierre Wolkenstein
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Nicolas de Prost
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Service de Médecine Intensive et Réanimation, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EpiDermE, Univ Paris Est Créteil Val de Marne, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
33
|
Moghadam P, Billard K, Lalevée S, Motavasseli D, Sbidian E, De Prost N, Pariat J, Ingen-Housz-Oro S. Heterotopic ossification: An unusual sequela of toxic epidermal necrolysis. J Eur Acad Dermatol Venereol 2023; 37:e352-e354. [PMID: 36308043 DOI: 10.1111/jdv.18697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Accepted: 10/25/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Parna Moghadam
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Karine Billard
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Sophie Lalevée
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Damien Motavasseli
- Physical Medicine and Rehabilitation Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Emilie Sbidian
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| | - Nicolas De Prost
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Intensive Care Unit Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Jacques Pariat
- Department of Orthopedic Surgery, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| |
Collapse
|
34
|
Assier H, Kouby F, Ingen-Housz-Oro S, Roux C. Severe allergic contact connubial dermatitis to Nigella Sativa Seed Oil due to repeated contacts to beard cosmetics. Contact Dermatitis 2023; 88:245-246. [PMID: 36494318 DOI: 10.1111/cod.14266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 12/06/2022] [Accepted: 12/07/2022] [Indexed: 12/14/2022]
Affiliation(s)
- Haudrey Assier
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référencedes dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| | - Floriane Kouby
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référencedes dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Université Paris Est Créteil EpidermE, Créteil, France
| | - Camille Roux
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| |
Collapse
|
35
|
Ingen-Housz-Oro S, Schmidt V, Ameri MM, Abe R, Brassard A, Mostaghimi A, Paller AS, Romano A, Didona B, Kaffenberger BH, Ben Said B, Thong BYH, Ramsay B, Brezinova E, Milpied B, Mortz CG, Chu CY, Sotozono C, Gueudry J, Fortune DG, Dridi SM, Tartar D, Do-Pham G, Gabison E, Phillips EJ, Lewis F, Salavastru C, Horvath B, Dart J, Setterfield J, Newman J, Schulz JT, Delcampe A, Brockow K, Seminario-Vidal L, Jörg L, Watson MP, Gonçalo M, Lucas M, Torres M, Noe MH, Hama N, Shear NH, O’Reilly P, Wolkenstein P, Romanelli P, Dodiuk-Gad RP, Micheletti RG, Tiplica GS, Sheridan R, Rauz S, Ahmad S, Chua SL, Flynn TH, Pichler W, Le ST, Maverakis E, Walsh S, French LE, Brüggen MC. Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. Orphanet J Rare Dis 2023; 18:33. [PMID: 36814255 PMCID: PMC9945700 DOI: 10.1186/s13023-023-02631-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 02/06/2023] [Indexed: 02/24/2023] Open
Abstract
BACKGROUND Long-term sequelae are frequent and often disabling after epidermal necrolysis (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)). However, consensus on the modalities of management of these sequelae is lacking. OBJECTIVES We conducted an international multicentric DELPHI exercise to establish a multidisciplinary expert consensus to standardize recommendations regarding management of SJS/TEN sequelae. METHODS Participants were sent a survey via the online tool "Survey Monkey" consisting of 54 statements organized into 8 topics: general recommendations, professionals involved, skin, oral mucosa and teeth, eyes, genital area, mental health, and allergy workup. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). Results were analyzed according to the RAND/UCLA Appropriateness Method. RESULTS Fifty-two healthcare professionals participated. After the first round, a consensus was obtained for 100% of 54 initially proposed statements (disagreement index < 1). Among them, 50 statements were agreed upon as 'appropriate'; four statements were considered 'uncertain', and ultimately finally discarded. CONCLUSIONS Our DELPHI-based expert consensus should help guide physicians in conducting a prolonged multidisciplinary follow-up of sequelae in SJS-TEN.
Collapse
Affiliation(s)
- S. Ingen-Housz-Oro
- grid.412116.10000 0004 1799 3934Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000 Créteil, France ,ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,grid.410511.00000 0001 2149 7878EpiDermE, Université Paris Est Créteil, Créteil, France
| | - V. Schmidt
- grid.410567.1University Hospital Basel, Basel, Switzerland ,grid.7400.30000 0004 1937 0650Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - M. M. Ameri
- grid.7400.30000 0004 1937 0650Faculty of Medicine, University of Zurich, Zurich, Switzerland ,grid.412004.30000 0004 0478 9977Department of Dermatology, University Hospital Zurich, Zurich, Switzerland ,grid.507894.70000 0004 4700 6354Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
| | - R. Abe
- grid.260975.f0000 0001 0671 5144Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - A. Brassard
- grid.413079.80000 0000 9752 8549Department of Dermatology, UC Davis Medical Center, Sacramento, CA USA
| | - A. Mostaghimi
- grid.62560.370000 0004 0378 8294Department of Dermatology, Brigham and Women’s Hospital, Boston, MA USA
| | - A. S. Paller
- grid.16753.360000 0001 2299 3507Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL USA
| | - A. Romano
- grid.419843.30000 0001 1250 7659Oasi Research Institute-IRCCS, Troina, Italy
| | - B. Didona
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.419457.a0000 0004 1758 0179Rare Disease Unit, I Dermatology Division, Istituto Dermopatico Dell’Immacolata, IRCCS, Rome, Italy
| | - B. H. Kaffenberger
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.412332.50000 0001 1545 0811The Ohio State University Wexner Medical Center Division of Dermatology, Upper Arlington, OH USA
| | - B. Ben Said
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,Department of Dermatology, CHU Edouard Herriot, Lyon, France
| | - B. Y. H. Thong
- grid.240988.f0000 0001 0298 8161Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
| | - B. Ramsay
- grid.415522.50000 0004 0617 6840Department of Dermatology, University Hospital Limerick, Limerick, Ireland
| | - E. Brezinova
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.10267.320000 0001 2194 0956First Department of Dermatovenereology, Masaryk University Faculty of Medicine, St. Ann’s Faculty Hospital in Brno, Brno, Czech Republic
| | - B. Milpied
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,grid.412041.20000 0001 2106 639XDepartment of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France
| | - C. G. Mortz
- grid.7143.10000 0004 0512 5013Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark
| | - C. Y. Chu
- grid.19188.390000 0004 0546 0241Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, 10002 Taiwan
| | - C. Sotozono
- grid.272458.e0000 0001 0667 4960Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Hirokoji-Agaru, Kawaramach-Dori, Kamigyo-Ku, Kyoto, 602-0841 Japan
| | - J. Gueudry
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,grid.417615.0Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France
| | - D. G. Fortune
- grid.10049.3c0000 0004 1936 9692Department of Psychology, University of Limerick, Limerick, Ireland
| | - S. M. Dridi
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,grid.416670.2MICORALIS Laboratory, Department of Periodontology, Faculty of Dentistry, Côte d’Azur University, Saint Roch Hospital, Nice, France
| | - D. Tartar
- grid.27860.3b0000 0004 1936 9684Department of Dermatology, University of California Davis, Sacramento, CA USA
| | - G. Do-Pham
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,grid.414145.10000 0004 1765 2136Department of Internal Medicine, Centre Hospitalier Intercommunal de Créteil, Créteil, France
| | - E. Gabison
- grid.417888.a0000 0001 2177 525XFondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - E. J. Phillips
- grid.1025.60000 0004 0436 6763Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA Australia ,grid.412807.80000 0004 1936 9916Department of Medicine, Vanderbilt University Medical Center, Nashville, TN USA
| | - F. Lewis
- grid.425213.3St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospital, London, UK
| | - C. Salavastru
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - B. Horvath
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.4830.f0000 0004 0407 1981Department of Dermatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
| | - J. Dart
- grid.83440.3b0000000121901201Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK
| | - J. Setterfield
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.420545.20000 0004 0489 3985Department of Oral Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
| | - J. Newman
- grid.429705.d0000 0004 0489 4320Department of Dermatology, King’s College Hospital NHS Foundation Trust, London, UK
| | - J. T. Schulz
- grid.32224.350000 0004 0386 9924Division of Burns, Massachusetts General Hospital, Boston, 02114 USA
| | - A. Delcampe
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France ,grid.417615.0Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France ,grid.417888.a0000 0001 2177 525XFondation Ophtalmologique Adolphe de Rothschild, Paris, France ,grid.411119.d0000 0000 8588 831XDepartment of Ophthalmology, CHU Bichat-Claude Bernard, Paris, France
| | - K. Brockow
- grid.6936.a0000000123222966Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany
| | - L. Seminario-Vidal
- grid.170693.a0000 0001 2353 285XDepartment of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, FL USA
| | - L. Jörg
- grid.412004.30000 0004 0478 9977Department of Dermatology, University Hospital Zurich, Zurich, Switzerland ,grid.5734.50000 0001 0726 5157Division of Allergology and Clinical Immunology, Department of Pneumology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - M. P. Watson
- grid.439257.e0000 0000 8726 5837Cornea and External Eye Disease Service, Moorfields Eye Hospital, London, UK
| | - M. Gonçalo
- grid.28911.330000000106861985Department of Dermatology, Coimbra University Hospital Center, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - M. Lucas
- grid.1012.20000 0004 1936 7910Medical School, University of Western Australia, Perth, WA 6009 Australia ,grid.3521.50000 0004 0437 5942Department of Immunology, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine, Perth, WA 6009 Australia
| | - M. Torres
- grid.452525.1Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain
| | - M. H. Noe
- grid.62560.370000 0004 0378 8294Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - N. Hama
- grid.260975.f0000 0001 0671 5144Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - N. H. Shear
- grid.17063.330000 0001 2157 2938Department of Dermatology, University of Toronto, Toronto, ON Canada ,grid.413104.30000 0000 9743 1587Sunnybrook Health Sciences Centre, Toronto, ON Canada
| | - P. O’Reilly
- grid.10049.3c0000 0004 1936 9692Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
| | - P. Wolkenstein
- grid.412116.10000 0004 1799 3934Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000 Créteil, France ,ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - P. Romanelli
- grid.26790.3a0000 0004 1936 8606Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL USA
| | - R. P. Dodiuk-Gad
- grid.6451.60000000121102151Dermatology Department, Emek Medical Center, Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel ,grid.17063.330000 0001 2157 2938Department of Medicine, University of Toronto, Toronto, Canada
| | - R. G. Micheletti
- grid.25879.310000 0004 1936 8972Department of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
| | - G. S. Tiplica
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,2Nd Department of Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - R. Sheridan
- grid.415829.30000 0004 0449 5362Burn Service, Boston Shriners Hospital for Children, Boston, MA USA ,grid.32224.350000 0004 0386 9924Division of Burns, Massachusetts General Hospital, Boston, MA USA ,grid.38142.3c000000041936754XDepartment of Surgery, Harvard Medical School, Boston, MA USA
| | - S. Rauz
- grid.6572.60000 0004 1936 7486Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
| | - S. Ahmad
- grid.83440.3b0000000121901201Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK
| | - S. L. Chua
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.412563.70000 0004 0376 6589Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | - T. H. Flynn
- grid.460892.10000 0004 0389 5639Ophthalmology, Bon Secours Hospital, Cork, Ireland
| | - W. Pichler
- grid.482939.dADR-AC GmbH, Bern, Switzerland
| | - S. T. Le
- grid.413079.80000 0000 9752 8549Department of Dermatology, UC Davis Medical Center, Sacramento, CA USA
| | - E. Maverakis
- grid.413079.80000 0000 9752 8549Department of Dermatology, UC Davis Medical Center, Sacramento, CA USA
| | - S. Walsh
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.429705.d0000 0004 0489 4320Department of Dermatology, King’s College Hospital NHS Foundation Trust, London, UK
| | - L. E. French
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.411095.80000 0004 0477 2585Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany ,grid.26790.3a0000 0004 1936 8606Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL USA
| | - M. C. Brüggen
- ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France ,grid.7400.30000 0004 1937 0650Faculty of Medicine, University of Zurich, Zurich, Switzerland ,grid.412004.30000 0004 0478 9977Department of Dermatology, University Hospital Zurich, Zurich, Switzerland ,grid.507894.70000 0004 4700 6354Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
| |
Collapse
|
36
|
Weiss M, Assier H, Hotz C, Hua C, Thomas L, Wolkenstein P, Ingen-Housz-Oro S. Acute generalized exanthematous pustulosis: Clinico-biological profile and inducing drugs in 83 patients. J Eur Acad Dermatol Venereol 2023; 37:e776-e778. [PMID: 36734481 DOI: 10.1111/jdv.18940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Accepted: 02/01/2023] [Indexed: 02/04/2023]
Affiliation(s)
- M Weiss
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France
| | - H Assier
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - C Hotz
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - C Hua
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris est Créteil EpidermE, Créteil, France
| | - L Thomas
- Department of Pharmacovigilance, AP-HP, Henri-Mondor Hospital, Creteil University, Créteil, France
| | - P Wolkenstein
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Creteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris est Créteil EpidermE, Créteil, France
| |
Collapse
|
37
|
Laurent C, Ram-Wolff C, Ingen-Housz-Oro S, Beylot-Barry M, Barete S, Saillard C, Dupuy A, Bagot M, Adamski H. Bone involvement in primary cutaneous diffuse large B-cell lymphoma, leg-type. Clin Exp Dermatol 2023; 48:116-120. [PMID: 36730524 DOI: 10.1093/ced/llac044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 10/05/2022] [Indexed: 01/12/2023]
Abstract
Primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) is an aggressive cutaneous lymphoma. Bone involvement is rare and poorly described. We present five cases of PCDLBCL-LT with bone localization. In four cases, the bone involvement was diagnosed during the initial staging with positron emission tomography (PET) or computed tomography (CT) scan, and in the fifth case after tibial fracture during treatment with rituximab (RTX) and polychemotherapy (PCT). PCDLBCL-LT can be asymptomatic and involve bone sites distant from cutaneous lesions. None had other extracutaneous involvement. In our series, all patients received RTX-PCT as first-line chemotherapy and all had early relapses or progression. Second-line treatments had poor efficacy. Our series shows that bone involvement seems to be associated with poor prognosis in PCDLBCL-LT. Bone localization is not diagnosed with initial thoracic-abdominal-pelvic CT when asymptomatic and affecting the limbs only. If there is a suspicion of PCDLBCL-LT, patients should undergo systematic investigation with alternative imaging techniques, including PET, both at baseline and if there is any concern during follow-up.
Collapse
Affiliation(s)
- Claire Laurent
- Department of Dermatology, University Hospital of Rennes, Rennes, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Paris, France.,French Study Group on Cutaneous Lymphomas (GFELC)
| | - Saskia Ingen-Housz-Oro
- French Study Group on Cutaneous Lymphomas (GFELC).,Department of Dermatology, AP-HP, Henri-Mondor Hospital, Créteil, France
| | - Marie Beylot-Barry
- French Study Group on Cutaneous Lymphomas (GFELC).,Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Stephane Barete
- French Study Group on Cutaneous Lymphomas (GFELC).,Department of Dermatology, Pitié-Salpetrière Hospital, Paris, France
| | - Clemence Saillard
- Department of Dermatology, University Hospital of Rennes, Rennes, France
| | - Alain Dupuy
- Department of Dermatology, University Hospital of Rennes, Rennes, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Paris, France.,French Study Group on Cutaneous Lymphomas (GFELC)
| | - Henri Adamski
- Department of Dermatology, University Hospital of Rennes, Rennes, France.,French Study Group on Cutaneous Lymphomas (GFELC)
| |
Collapse
|
38
|
Traineau H, Charpentier C, Lepeule R, Ingen-Housz-Oro S, Hersant B, Urbina T, de Prost N, Hua C, Chosidow O. First-year recurrence rate of skin and soft tissue infections following an initial necrotizing soft tissue infection of the lower extremities: A retrospective cohort study of 93 patients. J Am Acad Dermatol 2023:S0190-9622(23)00088-9. [PMID: 36702443 DOI: 10.1016/j.jaad.2022.12.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 12/13/2022] [Accepted: 12/25/2022] [Indexed: 01/25/2023]
Affiliation(s)
- Hélène Traineau
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.
| | - Chloé Charpentier
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Raphaël Lepeule
- Antimicrobial Stewardship Team, Department of Prevention, Diagnosis, and Treatment of Infections, APHP, Henri Mondor Hospital, Creteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France; Université Paris Est de Créteil EpidermE, UPEC, Créteil, France
| | - Barbara Hersant
- Department of Plastic Surgery, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Tomas Urbina
- Department of Intensive Care Medicine, AP-HP, Saint Antoine Hospital, Paris, France
| | - Nicolas de Prost
- Department of Intensive Care Medicine, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Camille Hua
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| |
Collapse
|
39
|
Giraud-Kerleroux L, Ingen-Housz-Oro S, De Prost N, Zeghbib N, Fiani C, Mongereau M, Gary C, Hirsch G, Hua C, Duong TA. Store and forward Teledermatology for epidermal necrolysis management: Experience of a French reference centre. J Eur Acad Dermatol Venereol 2023; 37:e110-e112. [PMID: 35993679 DOI: 10.1111/jdv.18550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 08/16/2022] [Indexed: 12/15/2022]
Affiliation(s)
- Laura Giraud-Kerleroux
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, Groupe Hospitalier de l'est Francilien - Site Marne-La-Vallée, Jossigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris Est Créteil Epiderme, Créteil, France
| | - Nicolas De Prost
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Intensive Care Unit APHP, Henri Mondor Hospital, Créteil, France
| | - Narimane Zeghbib
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France
| | - Caroline Fiani
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France
| | - Margaux Mongereau
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France
| | - Charlotte Gary
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France
| | - Gaëlle Hirsch
- Department of Dermatology, Groupe Hospitalier de l'est Francilien - Site Marne-La-Vallée, Jossigny, France
| | - Camille Hua
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Tu-Anh Duong
- Department of Dermatology AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
40
|
Roux C, Ben Said B, Milpied B, Bernier C, Staumont-Sallé D, Dezoteux F, Soria A, Barbaud A, Valeyrie-Allanore L, Tétart F, Bellon N, Lebrun-Vignes B, Gener G, Paul M, Ingen-Housz-Oro S, Assier H. Skin Testing and Drug Provocation Tests in Epidermal Necrolysis: A French Experience. J Allergy Clin Immunol Pract 2022; 10:3252-3261.e2. [PMID: 35870724 DOI: 10.1016/j.jaip.2022.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 06/28/2022] [Accepted: 07/07/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND There are limited data on the use of skin testing, other than patch testing, and challenges in the evaluation of epidermal necrolysis (EN), including Stevens-Johnson syndrome and toxic epidermal necrolysis. OBJECTIVE To report a French multicenter experience in skin testing and challenges in EN, and investigate the factors associated with tests' positivity. METHODS All patients who were evaluated by patch tests (PTs), skin prick tests, intradermal tests (IDTs), or drug provocation tests (DPTs) for EN between 2010 and 2020 were retrospectively included through 2 French drug reaction networks. RESULTS In total, 113 patients were included from 8 centers. Median (interquartile range) time from EN to hypersensitivity workup was 7.9 months (5.1-15 months). All patients had PTs, 17 (15%) had skin prick tests or IDTs with delayed readings and 32 (28.3%) had DPTs. One mild reaction occurred after a DPT. Overall, 22 patients (19.5%) had positive PTs, and the only factors associated with positivity were Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) score and drug class. Only 1 IDT was positive but considered irrelevant. The DPTs were never performed to prove responsibility of a highly suspected drug but were used to confirm current tolerance of needed medications. CONCLUSIONS Allergological workup in EN, performed by specialists involved in EN, seems safe. Skin tests, although of limited sensitivity, can be helpful for considering the reintroduction of essential drugs according to a benefit-to-risk decision. We propose an algorithm for approaching hypersensitivity testing in patients with EN, to be adapted to each patient.
Collapse
Affiliation(s)
- Camille Roux
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Benoit Ben Said
- Department of Allergy and Clinical Immunology, Edouard Herriot Hospital, HCL, Claude Bernard Lyon 1 University, Lyon, France; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France
| | - Brigitte Milpied
- Department of Allergy and Clinical Immunology, Edouard Herriot Hospital, HCL, Claude Bernard Lyon 1 University, Lyon, France; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; Department of Dermatology, National Reference Center for Rare Skin Diseases, University of Bordeaux, Bordeaux, France
| | - Claire Bernier
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Delphine Staumont-Sallé
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology, Lille University Hospital, Lille, France
| | - Frédéric Dezoteux
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology, Lille University Hospital, Lille, France
| | - Angèle Soria
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology and Allergy, Tenon Hospital, AP-HP, Sorbonne University, Paris, France
| | - Annick Barbaud
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology and Allergy, Tenon Hospital, AP-HP, Sorbonne University, Paris, France
| | - Laurence Valeyrie-Allanore
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Private Practice, Saint-Mandé, France
| | - Florence Tétart
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology, Rouen University Hospital, Normandie University, Rouen, France
| | - Nathalia Bellon
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Dermatology, Necker Hospital, AP-HP, Paris, France
| | - Bénédicte Lebrun-Vignes
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Department of Pharmacology, Pharmacovigilance Unit, Pitié-Salpétrière Hospital, AP-HP, Paris, France; Paris Est Créteil University, EpiDermE, Créteil, France
| | - Gwendeline Gener
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Muriel Paul
- Department of Hospital Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) Group, Paris, France; Paris Est Créteil University, EpiDermE, Créteil, France
| | - Haudrey Assier
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France; Department of Allergy and Clinical Immunology, Edouard Herriot Hospital, HCL, Claude Bernard Lyon 1 University, Lyon, France; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France.
| |
Collapse
|
41
|
Wang L, Rocas D, Dalle S, Sako N, Pelletier L, Martin N, Dupuy A, Tazi N, Balme B, Vergier B, Beylot-Barry M, Carlotti A, Bagot M, Battistella M, Chaby G, Ingen-Housz-Oro S, Gaulard P, Ortonne N. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. Br J Dermatol 2022; 187:970-980. [PMID: 35895386 PMCID: PMC10087773 DOI: 10.1111/bjd.21791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 07/04/2022] [Accepted: 07/22/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype (pcTFH-PTCL) are poorly characterized, and often compared to, but not corresponding with, mycosis fungoides (MF), Sézary syndrome, primary cutaneous CD4+ lymphoproliferative disorder, and skin manifestations of angioimmunoblastic T-cell lymphomas (AITL). OBJECTIVES We describe the clinicopathological features of pcTFH-PTCL in this original series of 23 patients, and also characterize these cases molecularly. METHODS Clinical and histopathological data of the selected patients were reviewed. Patient biopsy samples were also analysed by targeted next-generation sequencing. RESULTS All patients (15 men, eight women; median age 66 years) presented with skin lesions, without systemic disease. Most were stage T3b, with nodular (n = 16), papular (n = 6) or plaque (atypical for MF, n = 1) lesions. Three (13%) developed systemic disease and died of lymphoma. Nine (39%) patients received more than one line of chemotherapy. Histologically, the lymphomas were CD4+ T-cell proliferations, usually dense and located in the deep dermis (n = 14, 61%), with the expression of at least two TFH markers (CD10, CXCL13, PD1, ICOS, BCL6), including three markers in 16 cases (70%). They were associated with a variable proportion of B cells. Eight patients were diagnosed with an associated B-cell lymphoproliferative disorder (LPD) on biopsy, including Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (n = 3), EBV+ LPD (n = 1) and monotypic plasma cell LPD (n = 4). Targeted sequencing showed four patients to have a mutated TET2-RHOAG17V association (as frequently seen in AITL) and another a TET2/DNMT3A/PLCG1/SETD2 mutational profile. The latter patient, one with a TET2-RHOA association, and one with no detected mutations, developed systemic disease and died. Five other patients showed isolated mutations in TET2 (n = 1), PLCG1 (n = 2), SETD2 (n = 1) or STAT5B (n = 1). CONCLUSIONS Patients with pcTFH-PTCL have pathological and genetic features that overlap with those of systemic lymphoma of TFH derivation. Clinically, most remained confined to the skin, with only three patients showing systemic spread and death. Whether pcTFH-PTCL should be integrated as a new subgroup of TFH lymphomas in future classifications is still a matter of debate. What is already known about this topic? There is a group of cutaneous lymphomas that express T-follicular helper (TFH) markers that do not appear to correspond to existing World Health Organization diagnostic entities. These include mycosis fungoides, Sézary syndrome, or primary cutaneous CD4+ small/medium-sized T-cell lymphoproliferative disorder or cutaneous extensions of systemic peripheral T-cell lymphomas (PTCL) with TFH phenotype. What does this study add? This is the first large original series of patients with a diagnosis of primary cutaneous PTCL with a TFH phenotype (pcTFH-PTCL) to be molecularly characterized. pcTFH-PTCL may be a standalone group of cutaneous lymphomas with clinicopathological and molecular characteristics that overlap with those of systemic TFH lymphomas, such as angioimmunoblastic T-cell lymphoma, and does not belong to known diagnostic groups of cutaneous lymphoma. This has an impact on the treatment and follow-up of patients; the clinical behaviour needs to be better clarified in further studies to tailor patient management.
Collapse
Affiliation(s)
- Luojun Wang
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Delphine Rocas
- Department of Pathology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Stéphane Dalle
- Department of Dermatology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Nouhoum Sako
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Laura Pelletier
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nadine Martin
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Aurélie Dupuy
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nadia Tazi
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France
| | - Brigitte Balme
- Department of Pathology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Béatrice Vergier
- Department of Pathology, CHU de Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.,INSERM, U1312, Université de Bordeaux, 33000, Bordeaux, France
| | - Marie Beylot-Barry
- INSERM, U1312, Université de Bordeaux, 33000, Bordeaux, France.,Department of Dermatology, CHU de Bordeaux, Saint-André Hospital, 33000, Bordeaux, France
| | - Agnès Carlotti
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Cochin Hospital, 75014, Paris, France
| | - Martine Bagot
- Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, 75010, Université Paris Cité, Paris, France
| | - Maxime Battistella
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, 75010, Université Paris Cité, Paris, France
| | - Guillaume Chaby
- Department of Dermatology, CHU d'Amiens-Picardie, Hôpital Sud, 80054, Amiens, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France
| | - Philippe Gaulard
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nicolas Ortonne
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| |
Collapse
|
42
|
Welfringer-Morin A, Barroil M, Fraitag S, Szablewski V, Boccara O, Lacour JP, Chiaverini C, Bagot M, Ram-Wolff C, Vignon-Pennamen MD, Dalle S, D'incan M, Amatore F, Beylot-Barry M, Vergier B, Mazereeuw-Hautier J, Tedbirt B, Quereux G, Carpentier O, Skowron F, Bertrand Y, Van Eeckhout P, Dekeuleneer V, Nardin C, Adamski H, Ingen-Housz-Oro S, Dereure O, Bodemer C. Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients. Dermatology 2022; 239:132-139. [PMID: 36349768 DOI: 10.1159/000526788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 06/21/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood. METHODS This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients' clinical and histological characteristics, treatments, and disease outcome (for patients followed for more than 12 months) were analysed. RESULTS Forty-six patients were included (median age at diagnosis: 11 years; M:F sex ratio: 3:1) with 39 (85%) followed for at least 12 months. Thirty-nine patients (85%) had stage I MF. Hypopigmented patches were observed in 48% and folliculotropism in 43% patients. Immunophenotype of the skin infiltrate was predominantly CD8+ in 17% of patients. Initial management included a wait-and-see strategy in 6/39 (15%), skin-directed treatment in 27 (69%), and systemic treatment in 6 (15%) patients, respectively, with partial or complete clinical response (PR or CR) observed in 28 patients (72%). 14/39 patients (36%) relapsed after initial response. After a median follow-up period of 54 months, disease status at last news was PR or CR in 31/39 (79%), stable disease in 6 (15%), and progression in 2 (5%) patients. Histological transformation was observed in 3/39 (8%). Of the 15 patients followed until adulthood, 13 (87%) had persistent MF. DISCUSSION This survey confirms the high frequency of hypopigmented and folliculotropic lesions and of CD8+ immunophenotype compared to adult MF patients. The long-term course is usually indolent but transformation may occur sometimes long after disease onset and the disease may persist during adulthood.
Collapse
Affiliation(s)
- Anne Welfringer-Morin
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France,
| | - Marion Barroil
- Department of Dermatology, University of Montpellier and INSERM U1058, Montpellier, France
| | - Sylvie Fraitag
- Department of Pathology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| | | | - Olivia Boccara
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| | - Jean-Philippe Lacour
- Department of Dermatology, CHU de Nice, Université Nice Côte d'Azur, Nice, France
| | - Christine Chiaverini
- Department of Dermatology, CHU de Nice, Université Nice Côte d'Azur, Nice, France
| | - Martine Bagot
- Department of Dermatology, Hospital Saint Louis, APHP. Université de Paris, INSERM UMR 976, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Hospital Saint Louis, APHP. Université de Paris, INSERM UMR 976, Paris, France
| | | | - Stéphane Dalle
- Department of Dermatology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Michel D'incan
- Department of Dermatology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Florent Amatore
- Department of Dermatology, Hospital la Timone, Université Aix-Marseille, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Marie Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, INSERM U1053 Oncogenèse des lymphomes cutanés, Université de Bordeaux, Bordeaux, France
| | - Béatrice Vergier
- Department of Pathology, CHU de Bordeaux, INSERM U1053 Oncogenèse des lymphomes cutanés, Université de Bordeaux, Bordeaux, France
| | | | | | - Gaelle Quereux
- Department of Dermatology, Hotel Dieu, CHU de Nantes, Nantes, France
| | - Olivier Carpentier
- Department of Dermatology, Hospital Claude Huriez, CHRU Lille, Lille, France
| | | | - Yves Bertrand
- Department of Hematology, Institut d'hématologie et oncologie pediatrique, Lyon, France
| | - Pascal Van Eeckhout
- Department of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Valérie Dekeuleneer
- Department of Dermatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Charlee Nardin
- Department of Dermatology, CHU de Besancon, INSERM UMR 1098, Université de Franche-Comté, Besancon, France
| | - Henri Adamski
- Department of Dermatology, CHU Pontchaillou, Rennes, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Hospital Henri Mondor, APHP, University Paris Est Créteil EpiDermE, Creteil, France
| | - Olivier Dereure
- Department of Dermatology, University of Montpellier and INSERM U1058, Montpellier, France
| | - Christine Bodemer
- Department of Dermatology, Hospital Necker-Enfants Malades, APHP. Centre-Université de Paris, Paris, France
| |
Collapse
|
43
|
Colboc H, Bettuzzi T, Badrignans M, Bazin D, Boury A, Letavernier E, Frochot V, Tang E, Moguelet P, Ortonne N, de Prost N, Ingen-Housz-Oro S, Daudon M. Relationship between calcinosis cutis in epidermal necrolysis and caspofungin, a physicochemical investigation. CR CHIM 2022. [DOI: 10.5802/crchim.202] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
44
|
Ingen-Housz-Oro S, Thibault C, Sohier P, Dupin N. Regarding "Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin". Oncologist 2022; 27:e825-e826. [PMID: 36036595 PMCID: PMC9526490 DOI: 10.1093/oncolo/oyac170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 07/01/2022] [Indexed: 11/12/2022] Open
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, AP-HP, Univ Paris-est Créteil EpidermE, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions (TOXIBUL), Créteil, France
| | | | - Pierre Sohier
- Pathology Department, Cochin Hospital, AP-HP, AP-HP.Centre-Université Paris Cité, Paris, France
| | - Nicolas Dupin
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France
| |
Collapse
|
45
|
Guerrois F, Hassan E, Bettuzzi T, Seta V, Goulvestre C, Jelti L, Belmondo T, Wolkenstein P, Aractingi S, Ingen-Housz-Oro S, Dupin N. Bullous pemphigoid: Three main clusters defining 3 outcome profiles. J Am Acad Dermatol 2022; 87:359-365. [PMID: 35483492 DOI: 10.1016/j.jaad.2022.04.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 02/27/2022] [Accepted: 04/08/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. Its presentation is polymorphic. OBJECTIVE To investigate different clinical and biological profiles of BP. METHODS We conducted a retrospective 2-center study including all BP patients seen between January 1, 2015, and February 28, 2021. We performed hierarchical clustering on principal components. RESULTS Three clusters were identified. Patients in cluster 1 (n = 155) were older than those in clusters 2 (n = 89) and 3 (n = 35; P < .0001), more frequently presented pauci-bullous BP (n = 63 [41%] vs 14 [16%] and 2 [6%], respectively; P < .0001) and had anti-BP230 antibodies in 87% of cases. More than 100 blisters were observed in 14 patients (40%) from cluster 3, versus 3 (2%) from cluster 1 and 0 (0%) from cluster 2 (P < .0001). Frequency of mucosal involvement was higher in cluster 3 (n = 32 [91%, including epiglottis in 40%] vs 11 [7%] and 34 [38%]; P < .0001). In clusters 2 and 3, 70% and 74% of patients had antibodies targeting only BP180. Those in cluster 3 received more lines of systemic treatment and experienced more relapses. LIMITATIONS Retrospective study without immunoelectron microscopy. CONCLUSION We identified 3 different BP clusters, including one corresponding to severe BP180+ BP230- BP with features common to mucous membrane pemphigoid.
Collapse
Affiliation(s)
| | - Elsa Hassan
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Thomas Bettuzzi
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; EpiDermE (Épidémiologie en Dermatologie et Évaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - Vannina Seta
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France; Cenpetence Center for Autoimmune Blistering Diseases MALIBUL, AP-HP, Cochin Hospital, Paris, France
| | - Claire Goulvestre
- Immunology and Biology Department, AP-HP, Cochin Hospital, Paris, France
| | - Lamia Jelti
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Thibaut Belmondo
- Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France; Immunology and Biology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | | | - Selim Aractingi
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France; Laboratoire de Biologie Cutanée, Institut Cochin, Inserm U1016, Université de Paris, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; EpiDermE (Épidémiologie en Dermatologie et Évaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France; Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France.
| | - Nicolas Dupin
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France; Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France; Laboratoire de Biologie Cutanée, Institut Cochin, Inserm U1016, Université de Paris, France
| |
Collapse
|
46
|
O’Reilly P, Meskell P, Whelan B, Kennedy C, Ramsay B, Coffey A, Fortune DG, Walsh S, Ingen-Housz-Oro S, Bunker CB, Wilson DM, Delaunois I, Dore L, Howard S, Ryan S. Psychotherapeutic interventions for burns patients and the potential use with Stevens-Johnson syndrome and toxic epidermal necrolysis patients: A systematic integrative review. PLoS One 2022; 17:e0270424. [PMID: 35759493 PMCID: PMC9236256 DOI: 10.1371/journal.pone.0270424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Accepted: 06/09/2022] [Indexed: 11/18/2022] Open
Abstract
Background
The existing evidence demonstrates that survivors of SJS/TEN have reported long-lasting psychological effects of their condition. Burns patients experience similar psychological effects. It is important to look at ways to help allay the psychological complications of SJS/TEN. As there is an absence of evidence on SJS/TEN psychotherapeutic interventions, it was judged to be beneficial to determine the evidence underpinning psychotherapeutic interventions used with burns patients.
Aims and objectives
The aim of this systematic integrative review was to synthesize the evidence relating to psychotherapeutic interventions used with adult burns patients and patients with SJS/TEN.
Method
The systematic review was guided by Whittemore and Knafl’s integrative review process and the PRISMA guidelines. Nine databases were searched for English and French language papers published January 2008 to January 2021. The protocol for the review was registered with PROSPERO.
Results
Following a screening process, 17 studies were included in the review. Two themes were identified using content analysis, (i) Empirically supported psychotherapeutic treatments, (ii) Alternative psychotherapeutic treatments. This review revealed no evidence on specific psychotherapeutic interventions for patients with SJS/TEN. Some of the interventions used with burns patients, viz. relaxation therapy, hypnosis and cognitive behavioral therapy showed some significant benefits. However, the evidence for burns patients is mainly focused on pain and pain anxiety as outcomes.
Conclusion
Following further research, some of the interventions deployed in burns patients may be applicable to SJS/TEN patients, particularly stress reduction techniques. In addition, the caring behaviours such as compassion, respect, and getting to know the patient as a person are important components to psychological care.
Collapse
Affiliation(s)
- Pauline O’Reilly
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- Health Research Institute, University of Limerick, Limerick, Ireland
- Health Implementation Science and Technology (HIST) Research Cluster, University of Limerick, Limerick, Ireland
- * E-mail:
| | - Pauline Meskell
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- Health Research Institute, University of Limerick, Limerick, Ireland
| | - Barbara Whelan
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- Health Research Institute, University of Limerick, Limerick, Ireland
| | - Catriona Kennedy
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- School of Nursing, Midwifery and Paramedic Practice, Robert Gordon University, Aberdeen, Scotland
| | - Bart Ramsay
- Charles Centre for Dermatology, University Hospital Limerick, ULHG, Limerick, Ireland
- School of Medicine, University of Limerick, Limerick, Ireland
| | - Alice Coffey
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- Health Research Institute, University of Limerick, Limerick, Ireland
- Health Implementation Science and Technology (HIST) Research Cluster, University of Limerick, Limerick, Ireland
| | - Donal G. Fortune
- Health Research Institute, University of Limerick, Limerick, Ireland
- Department of Psychology, University of Limerick, Limerick, Ireland
| | - Sarah Walsh
- Dermatology Department, King’s College Hospital, London, United Kingdom
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Univ Paris Est Créteil EpiDermE, Créteil, France
| | - Christopher B. Bunker
- Department of Dermatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
| | - Donna M. Wilson
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
| | - Isabelle Delaunois
- Regional Medical Library, University Hospital Limerick, Limerick, Ireland
| | - Liz Dore
- Glucksman Library, University of Limerick, Limerick, Ireland
| | - Siobhan Howard
- Health Research Institute, University of Limerick, Limerick, Ireland
- Department of Psychology, University of Limerick, Limerick, Ireland
| | - Sheila Ryan
- Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- Charles Centre for Dermatology, University Hospital Limerick, ULHG, Limerick, Ireland
| |
Collapse
|
47
|
Hankard A, Ingen-Housz-Oro S, El Karoui K, Paule R, Lioger B, Brihaye B, Battistella M, Jobard S, Magnant J, Diot E, Bigot A, Ferreira-Maldent N, Deriaz S, Cook AR, Henique H, Maillot F, Aouba A, Audemard-Verger A. IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series. Clin Rheumatol 2022; 41:3119-3123. [PMID: 35713822 DOI: 10.1007/s10067-022-06181-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 04/11/2022] [Accepted: 04/13/2022] [Indexed: 11/03/2022]
Abstract
OBJECTIVE There is currently no evidence of the possible benefit of plasma cell-targeting therapies (PCTT) in immunoglobulin A (IgA) monoclonal gammopathy (MG) associated with IgA vasculitis (IgAV). We report the outcome of different PCTT regimens in a cohort of MG-IgAV. METHODS We used a French network to retrospectively describe the outcome of MG-IgAV patients treated with PCTT. RESULTS Five patients were included (mean age 65 years). All patients had severe baseline presentation including extensive necrotic purpura (n = 5), gastrointestinal involvement (n = 2), peripheral neuropathies (n = 2), and glomerulonephritis (n = 1). Two patients had IgA indolent multiple myeloma and three had IgA "MG of undetermined significance." Monotypic IgA deposition in the skin vessels wall was highlighted using an immunofluorescence assay. Cases of vasculitis in three patients (n = 3) were refractory to multiple line therapies, including cyclophosphamide (n = 3) or rituximab. Finally, PCTT including bortezomib plus cyclophosphamide and dexamethasone, bortezomib plus melphalan and prednisone, or bortezomib plus lenalidomide and dexamethasone were proposed, allowing complete remission in 4/5 patients without major adverse drug events. CONCLUSION This study suggests that the MG-IgAV phenotype might be distinctive of usual IgAV (severe and refractory to conventional immunosuppressive regimens) and supports the benefit of PCTT. This study sheds new light on the overall biology of IgAV, strengthening the pathogenic role of the monoclonal IgA component in IgAV.
Collapse
Affiliation(s)
| | | | | | - Romain Paule
- Department of Internal Medicine, Hôpital Foch, Suresne, France
| | - Bertrand Lioger
- Department of Internal Medicine, Hôpital de Blois, Blois, France
| | - Benoit Brihaye
- Department of Internal Medicine, CH Saint Quentin, Saint Quentin, France
| | | | - Stéphanie Jobard
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Julie Magnant
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Elisabeth Diot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Adrien Bigot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | | | - Sophie Deriaz
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Ann-Rose Cook
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Hélène Henique
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Francois Maillot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France.,University of Tours, Tours, France
| | - Achille Aouba
- Department of Internal Medicine, CHU de Caen, Caen, France
| | - Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France. .,University of Tours, Tours, France.
| | | |
Collapse
|
48
|
Kechichian E, Weill A, Ingen-Housz-Oro S, Assier H. Cimetidine and Racecadotril : Unusual Culprit Drugs of a Severe Cutaneous Adverse Reaction. Contact Dermatitis 2022; 87:451-452. [PMID: 35715974 DOI: 10.1111/cod.14176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Revised: 06/13/2022] [Accepted: 06/15/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Elio Kechichian
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Amandine Weill
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référence dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référence dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| | - Haudrey Assier
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référence dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| |
Collapse
|
49
|
Calmettes V, Badrignans M, Konstantinou MP, Tancrède-Bohin E, Vignon-Pennamen MD, Castel M, Pham-Ledard A, Le Roux-Villet C, Misery L, Schoenlaub P, Tronquoy AF, Cordel N, Ortonne N, Sohier P, Cellier L, Tournier E, De La Salle EM, Le Flahec G, Plantier F, Grootenboer-Mignot S, Jouen F, Hillion B, Aractingi S, Duvert-Lehembre S, Dupin N, Ingen-Housz-Oro S. IgA and IgG/IgA intercellular dermatosis: a clinicopathological case series of 15 patients. J Eur Acad Dermatol Venereol 2022; 36:e896-e898. [PMID: 35694900 DOI: 10.1111/jdv.18325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Accepted: 06/03/2022] [Indexed: 12/16/2022]
Affiliation(s)
- V Calmettes
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - M Badrignans
- Department of Pathology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - M P Konstantinou
- Department of Dermatology, University Hospital of Toulouse, Toulouse, France
| | - E Tancrède-Bohin
- Department of Dermatology, Saint Louis University Hospital, APHP, Paris, France
| | - M D Vignon-Pennamen
- Department of Pathology, Saint Louis University Hospital, APHP, Paris, France
| | - M Castel
- Department of Dermatology, University Hospital of Rouen, Rouen, France
| | - A Pham-Ledard
- Department of Dermatology, CHU Bordeaux and INSERM U1312, Bordeaux, France
| | - C Le Roux-Villet
- Department of Dermatology, University Hospital Avicenne, Bobigny, France
| | - L Misery
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - P Schoenlaub
- Department of Dermatology, Hopital d'Instruction des Armées, Brest, France
| | - A F Tronquoy
- Department of Dermatology, Hospital of Boulogne-sur-Mer, Boulogne-sur-Mer, France
| | - N Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, France
| | - N Ortonne
- Department of Pathology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - P Sohier
- Department of Pathology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - L Cellier
- Department of Pathology, University Hospital of Rouen, Rouen, France
| | - E Tournier
- Derpartment of Pathology, University Hospital of Toulouse, Toulouse, France
| | - E M De La Salle
- Department of Pathology, University Hospital of Lille, Lille, France
| | - G Le Flahec
- Department of Pathology, University Hospital of Brest, Brest, France
| | - F Plantier
- Cabinet de Pathologie Mathurin Moreau, Paris, France
| | | | - F Jouen
- Department of Immunology, University Hospital of Rouen, Rouen, France
| | - B Hillion
- Department of Dermatology, Hospital of Marne la Vallée, Jossigny, France
| | - S Aractingi
- Department of Dermatology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - S Duvert-Lehembre
- Department of Dermatology, Hospital of Dunkerque, Dunkerque, France.,Department of Dermatology, University Hospital of Lille, Lille, France
| | - N Dupin
- Department of Dermatology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| | -
- French Bullous Diseases Study Group Paris, Paris, France
| |
Collapse
|
50
|
Ingen-Housz-Oro S, Milpied B, Badrignans M, Carrera C, Elshot YS, Bensaid B, Segura S, Apalla Z, Markova A, Staumont-Sallé D, Marti-Marti I, Giavedoni P, Chua SL, Darrigade AS, Dezoteux F, Starace M, Torre AC, Riganti J, de Prost N, Lebrun-Vignes B, Bauvin O, Walsh S, Ortonne N, French LE, Sibaud V. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res 2022; 32:205-210. [PMID: 35377864 PMCID: PMC9377568 DOI: 10.1097/cmr.0000000000000819] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), bullous life-threatening reactions are rare. To better define the clinical and histological features, treatment, and prognosis of ICI-related severe blistering cutaneous eruptions. This retrospective case series was conducted between 2014/05/15 and 2021/04/15 by the dermatology departments of four international registries involved in drug reactions. Inclusion criteria were age ≥18 years old, skin eruption with blisters with detachment covering ≥1% body surface area and at least one mucous membrane involved, available pictures, and ICI as suspect drug. Autoimmune bullous disorders were excluded. Each participant medical team gave his own diagnosis conclusion: epidermal necrolysis (EN), severe lichenoid dermatosis (LD), or unclassified dermatosis (UD). After a standardized review of pictures, cases were reclassified by four experts in EN or LD/UD. Skin biopsies were blindly reviewed. Thirty-two patients were included. Median time to onset was 52 days (3-420 days). Cases were originally diagnosed as EN in 21 cases and LD/UD in 11 cases. After review by experts, 10/21 EN were reclassified as LD/UD. The following manifestations were more frequent or severe in EN: fever, purpuric macules, blisters, ocular involvement, and maximal detachment. Most patients were treated with topical with or without systemic corticosteroids. Eight patients (25%) died in the acute phase. The culprit ICI was not resumed in 92% of cases. In three patients, another ICI was given with a good tolerance. Histology did not reveal significant differences between groups. Severe blistering cutaneous drug reactions induced by ICI are often overdiagnosed as EN. Consensus for management is pending.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology department, AP-HP, Henri Mondor hospital, Créteil, France
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Univ Paris est Créteil EpidermE, Créteil, France
- European Task Force “Dermatology for cancer patients” of EADV
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
| | - Brigitte Milpied
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- European Task Force “Dermatology for cancer patients” of EADV
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Marine Badrignans
- Pathology department, AP-HP, Henri Mondor hospital, Créteil, France
- Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Cristina Carrera
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
- CIBERER Centro de investigaciones Biomedicas en Red de Enfermedades Raras Insituto de Salud Carlos III, Spain
- Pharmacovigilance Technical Committee Hospital Clinic Barcelona, Spain
| | - Yannick S. Elshot
- European Task Force “Dermatology for cancer patients” of EADV
- Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- Department of Dermatology, Amsterdam UMC, Univ. of Amsterdam, The Netherlands
| | - Benoit Bensaid
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Dermatology department, CHU Edouard Herriot, Lyon, France
| | - Sonia Segura
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
| | - Zoé Apalla
- European Task Force “Dermatology for cancer patients” of EADV
- Second Dermatology Department, Medical School, Aristotle University of Thessaloniki, Greece
| | - Alina Markova
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Dermatology, Weill Cornell Medical College, New York, NY, USA
| | - Delphine Staumont-Sallé
- FISARD group, Paris, France
- Dermatology Department, CHU Lille, University Lille, INFINITE U1286 Inserm, Lille, France
| | - Ignasi Marti-Marti
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Priscila Giavedoni
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Ser-Ling Chua
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Anne-Sophie Darrigade
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Frédéric Dezoteux
- FISARD group, Paris, France
- Dermatology Department, CHU Lille, University Lille, INFINITE U1286 Inserm, Lille, France
| | - Michela Starace
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology -IRCCS Policlinico di Sant’Orsola - Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Italy
| | - Ana Clara Torre
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Julia Riganti
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Nicolas de Prost
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- Intensive care unit, AP-HP, Henri Mondor hospital, Créteil, France
| | - Bénédicte Lebrun-Vignes
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Regional Pharmacovigilance Center, AP-HP, Pitié-Salpêtrière hospital, Paris, France
| | - Olivia Bauvin
- FISARD group, Paris, France
- Dermatology department, CHU Charles Nicolle, Rouen, France
| | - Sarah Walsh
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology, King’s College Hospital, London, United Kingdom
| | - Nicolas Ortonne
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- Pathology department, AP-HP, Henri Mondor hospital, Créteil, France
- Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Lars E. French
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan University (LMU) Munich, Munich, Germany
- Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL
| | - Vincent Sibaud
- European Task Force “Dermatology for cancer patients” of EADV
- Department of Oncodermatology, Claudius Regaud Institute and University Cancer Institute Toulouse Oncopole, Toulouse, France
| |
Collapse
|